

1 **Clinical Practice Guideline: Electrodiagnostic Testing**

2

3 **Date of Implementation: June 23, 2010**

4

5 **Product: Specialty**

6

7

8 **Table of Contents**

9 GUIDELINES ..... 2

10 Medically Necessary ..... 2

11 Nerve Conduction/Electromyography: Performed Together ..... 2

12 Nerve Conduction: Performed Alone ..... 4

13 Neuromuscular Junction Testing ..... 4

14 Somatosensory Evoked Potentials (SSEPs)..... 5

15 Not Medically Necessary..... 5

16 Unproven ..... 5

17 DESCRIPTION/BACKGROUND ..... 7

18 Electrodiagnostic Testing Nerve Conduction/Needle Electromyography ..... 8

19 H-reflex/F-wave Testing.....11

20 Macro EMG.....11

21 Surface EMG (SEMG) .....11

22 Somatosensory Evoked Potentials (SEPs).....12

23 Neuromuscular Junction Testing .....14

24 Automated Nerve Conduction Testing .....15

25 Electrodiagnostic Testing General Principles.....15

26 Carpal Tunnel Syndrome.....22

27 Radiculopathy.....22

28 Polyneuropathy/Mononeuropathy Multiplex.....22

29 Myopathy.....23

30 Motor Neuronopathy .....23

31 Plexopathy .....23

32 Neuromuscular Junction .....23

33 Frequency of Electrodiagnostic Testing in a Given Patient.....24

34 DOCUMENTATION GUIDELINES .....26

35 Documentation Required Justifying Electrodiagnostic Testing.....26

36 Inadequate Documentation .....26

1 EVIDENCE REVIEW.....27  
 2 Automated Nerve Conduction Testing .....27  
 3 Other Electrodiagnostic Testing .....30  
 4 Surface Electromyography (SEMG).....32  
 5 The Evaluation of Specific Neuromuscular Pathologies .....32  
 6 The Evaluation of Movement and Gait Disturbances.....32  
 7 The Evaluation of Functional Back Pain .....33  
 8 PRACTITIONER SCOPE AND TRAINING .....35  
 9 References .....36

10  
 11 **GUIDELINES**

12  
 13 **Medically Necessary**

14 **Nerve Conduction/Electromyography: Performed Together**

15 American Specialty Health – Specialty (ASH) considers nerve conduction velocity  
 16 (NCV) testing AND needle electromyography testing (NEMG) medically necessary  
 17 when they are conducted and interpreted at the same time for **ANY of the following**  
 18 **indications:**

- 19 • Myopathy, including but not limited to ANY of the following:
  - 20 ○ Inflammatory myopathy and myositis (i.e., polymyositis, dermatomyositis,
  - 21 inclusion body myositis)
  - 22 ○ Congenital and hereditary dystrophic and nondystrophic myopathies,
  - 23 including myotonic muscular dystrophy
  - 24 ○ Acquired myopathies (drug induced myopathy associated with statins,
  - 25 thyroid related)
  - 26 ○ Metabolic myopathies (such as McArdle disease)
- 27 • Disorder of brachial or lumbosacral plexus (e.g., inflammatory, idiopathic,
- 28 traumatic, infiltrative plexopathy, thoracic outlet syndrome, Parsonage Turner
- 29 syndrome)
- 30 • Motor or sensory neuropathy or ganglionopathy (e.g., Amyotrophic lateral
- 31 sclerosis, primary lateral sclerosis, progressive muscular atrophy or Kennedy's
- 32 Disease)
- 33 • Multifocal motor neuropathy
- 34 • Neuromuscular junction disorder (e.g., myasthenia gravis, Lambert-Eaton
- 35 myasthenic syndrome, botulism)
- 36 • Focal or generalized sensory and motor neuropathies including but not limited to
- 37 ANY of the following after failure of 4-6 weeks of conservative care (e.g., physical
- 38 therapy, exercise, bracing):
  - 39 ○ carpal tunnel syndrome
  - 40 ○ cubital tunnel syndrome or ulnar neuropathy

- 1                   ○ tarsal tunnel syndrome
- 2                   ○ cervical or lumbar radiculopathy
- 3       • Inflammatory/autoimmune polyneuropathy (e.g., Guillain-Barre syndrome,
- 4       chronic inflammatory demyelinating polyneuropathy [CIDP], mononeuritis
- 5       multiplex and neuropathy associated with rheumatologic disorders)
- 6       • Hereditary neuropathies (e.g., Charcot-Marie-Tooth disease, hereditary
- 7       neuropathy with liability to pressure palsies, Friedreich’s Ataxia)
- 8       • Diabetic polyneuropathy and diabetic radiculoplexus neuropathy (diabetic
- 9       amyotrophy)
- 10      • Metabolic and nutritional neuropathy (e.g., vitamin B12 or thiamine deficiency)
- 11      • Toxic neuropathy (associate with drugs vincristine, amiodarone, or environmental
- 12      toxins such as organophosphates)
- 13      • Infectious neuropathy (e.g., HIV, Lyme disease, Leprosy, polio)
- 14      • Cranial neuropathy (Bell’s or facial palsy)
- 15      • Idiopathic peripheral neuropathy
- 16      • Symptom-based presentation suggesting nerve root, peripheral nerve, muscle, or
- 17      neuromuscular junction involvement, when pre-test evaluations are inconclusive
- 18      and clinical assessment supports the need for the study, such as for ANY of the
- 19      following:
- 20      ○ Muscle weakness
- 21      ○ Muscle atrophy
- 22      ○ Muscle fasciculation
- 23      ○ Myokymia
- 24      ○ Myotonia
- 25      ○ Loss of dexterity
- 26      ○ Spasticity
- 27      ○ Hyperreflexia
- 28      ○ Sensory deficits
- 29      ○ Diplopia
- 30      ○ Ptosis
- 31      ○ Swallowing dysfunction
- 32      ○ Dysarthria
- 33      ○ Impaired bowel motility

### 1 **Nerve Conduction: Performed Alone**

2 Nerve conduction velocity (NCV) testing performed alone is considered medically  
3 necessary for ANY of the above indications, in ANY of the following clinical  
4 presentations:

- 5 • Current use of an anticoagulant
- 6 • Presence of significant lymphedema
- 7 • For facial nerve monitoring in Bells palsy
- 8 • Suspected peroneal/fibular nerve palsy
- 9 • Thoracic outlet syndrome
- 10 • Suspected tarsal tunnel syndrome
- 11 • Suspected acute nerve injury (within 3 weeks)
- 12 • Carpal tunnel syndrome with **BOTH** of the following:
  - 13 ○ with high pre-test probability (e.g., positive Tinel’s, thenar muscle atrophy
  - 14 or paresthesia in the radial three digits)
  - 15 ○ after failure of 4-6 weeks of conservative care (e.g., physical therapy,
  - 16 exercise, bracing)

17  
18 NEMG testing is considered medically necessary when performed for determination of  
19 precise muscle location for an injection (i.e., prior to botulism toxin injection for  
20 localization; prior to injection of phenol or other substances for nerve blocking or  
21 chemodenervation).

### 22 23 **Neuromuscular Junction Testing**

24 Neuromuscular junction testing is considered medically necessary for **ANY of the**  
25 **following indications:**

- 26 • Myopathy
- 27 • Motor neuropathy (e.g., ALS)
- 28 • Botulinum toxicity
- 29 • Myasthenia gravis
- 30 • Lambert Eaton myasthenic syndrome
- 31 • The presence of any of the following:
  - 32 ○ Diplopia
  - 33 ○ Dysphagia and dysarthria
  - 34 ○ Fatigue/weakness that progresses with repetitive activity

35  
36 Single fiber EMG (SFEMG) is medically necessary for diagnosis of myasthenia gravis  
37 if repetitive nerve stimulation is negative or inconclusive.

## 1 **Somatosensory Evoked Potentials (SSEPs)**

2 Somatosensory evoked potentials (SSEPs) are considered medically necessary when  
3 prior diagnostic testing has failed to confirm a diagnosis for **ANY** of the following:

- 4 • Coma following traumatic, hypoxic/ischemic and other diffuse brain injuries
- 5 • Myoclonus
- 6 • Multiple sclerosis and other demyelinating diseases (e.g.,  
7 adrenoleukodystrophy, adrenomyeloneuropathy, metachromatic  
8 leukodystrophy, and pelizaeus-merzbacher disease)
- 9 • Spinocerebellar degeneration
- 10 • Spinal cord lesions secondary to trauma when the need for surgical intervention is  
11 uncertain
- 12 • Acute (within 72 hours) anoxic encephalopathy
- 13 • To localize the cause of a central nervous system deficit seen on exam, but not  
14 explained by lesions seen on CT or MRI
- 15 • Suspected brain death

## 16 **Not Medically Necessary**

17 Neuromuscular junction testing for **ANY** other indication is considered not medically  
18 necessary.  
19

20  
21 Nerve conduction velocity testing when performed with NEMG testing for **ANY** other  
22 indication, including the following is considered not medically necessary:

- 23 • Screening of the general population, in the absence of related symptoms
- 24 • Screening, monitoring of disease intensity or monitoring of treatment  
25 efficacy for polyneuropathy of diabetes
- 26 • Screening, monitoring of disease intensity or monitoring of treatment efficacy for  
27 end stage renal disease

## 28 **Unproven**

29 The following electrodiagnostic tests are each considered unproven:

- 30 • Nerve conduction velocity (NCV) testing performed without needle  
31 electromyography, other than when performed for follow-up testing, with current  
32 use of anticoagulants, the presence of lymphedema, or for carpal tunnel  
33 syndrome
- 34 • Nerve conduction testing where the interpretation is delayed and not completed at  
35 the time of testing
- 36 • Nerve conduction velocity testing performed without the direct supervision of a  
37 trained electrodiagnostic physician
- 38 • Automated noninvasive nerve conduction testing (e.g., NC-stat System,  
39 Brevio<sup>®</sup> nerve conduction monitoring system)
- 40 • Macro electromyography (EMG)
- 41

- 1 • Surface electromyography (e.g., surface EMG [SEMG], surface scanning EMG,
- 2 high-density SEMG, HD-SEMG) and macro EMGs
- 3 • Paraspinal SEMG
- 4 • Needle electromyography study performed without a nerve conduction
- 5 velocity study and/or late response study for any indication, other than
- 6 injection localization or intraoperative monitoring
- 7 • Exclusive testing of intrinsic foot muscles in the diagnosis of proximal lesions
- 8 • Definitive diagnostic conclusions based on paraspinal EMG in regions bearing
- 9 scar of past surgeries (e.g., previous laminectomies)
- 10 • Pattern-setting limited limb muscle examinations, without paraspinal
- 11 muscle testing for a diagnosis of radiculopathy
- 12 • EMG testing shortly after trauma, before EMG abnormalities would have
- 13 reasonably had time to develop
- 14 • Multiple uses of EMG in the same patient at the same location of the same limb
- 15 for the purpose of optimizing botulinum toxin injections

16  
 17 SSEPs are considered unproven for ANY indication other than those listed above;  
 18 including the evaluation of disorders of the lumbosacral roots, such as radiculopathies,  
 19 thoracic root disorders, or cervical root disorders.

20  
 21 Current Perception Threshold/Sensory Nerve Conduction Threshold TEST (sNCT) – is  
 22 not covered by Medicare. This procedure is different and distinct from assessment of  
 23 nerve conduction velocity, amplitude, and latency. It is also different from short-latency  
 24 somatosensory evoked potentials.

25

CPT®/HCPCS Code	CPT®/HCPCS Code Description
95885	Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; limited (List separately in addition to code for primary procedure)
95886	Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; complete, five or more muscles studied, innervated by three or more nerves or four or more spinal levels (List separately in addition to code for primary procedure)
95887	Needle electromyography, non-extremity (cranial nerve supplied or axial) muscle(s) done with nerve conduction, amplitude and latency/velocity study (List separately in addition to code for primary procedure)

<b>CPT®/HCPCS Code</b>	<b>CPT®/HCPCS Code Description</b>
95905	Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and latency/velocity study, each limb, includes F-wave study when performed, with interpretation and report
95907	Nerve conduction studies; 1-2 studies
95908	Nerve conduction studies; 3-4 studies
95909	Nerve conduction studies; 5-6 studies
95910	Nerve conduction studies; 7-8 studies
95911	Nerve conduction studies; 9-10 studies
95912	Nerve conduction studies; 11-12 studies
95913	Nerve conduction studies; 13 or more studies
95925	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper limbs
95926	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower limbs
95927	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in the trunk or head
95937	Neuromuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any 1 method
95938	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs
S3900	Surface electromyography (EMG)

1  
2  
3  
4  
5  
6  
7  
8

***DESCRIPTION/BACKGROUND***

This guideline addresses electrodiagnostic testing, including nerve conduction (NCV) studies, neuromuscular junction testing, electromyography (EMG) studies (including surface EMG). This guideline adopts many of the recommendations for the clinical necessity, contraindications, and proper performance of nerve conduction studies, needle electromyography, and somatosensory evoked potentials (SEPs) from the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM).

1 Electrodiagnostic studies are frequently used to evaluate a subset of patients with suspected  
2 neuromuscular disorders and include needle electromyography and other nerve stimulation  
3 tests such as nerve conduction studies. Electrodiagnostic testing may provide an important  
4 means of diagnosing conditions attributable to nerve, muscle, or neuromuscular junction  
5 weakness such as myopathies (muscle weakness), radiculopathies (nerve root disease),  
6 plexopathies (peripheral neuropathy), neuropathies (nerve disease), neuromuscular junction  
7 disorders, and nerve compression syndromes. In addition, electrodiagnostic testing may be  
8 indicated for symptom-based presentations, (e.g., pain in limb, muscle weakness) when  
9 appropriate pre-test evaluations are inconclusive and the clinical assessment unequivocally  
10 supports the need for the study (American Association of Neuromuscular and  
11 Electrodiagnostic Medicine [AANEM], 2010).

### 12 **Electrodiagnostic Testing Nerve Conduction/Needle Electromyography**

13 Nerve conduction studies (NCS), also referred to as nerve conduction velocity studies, are  
14 performed to diagnose disorders of the peripheral nervous system. Nerve conduction  
15 studies are used to measure action potentials resulting from peripheral nerve stimulation  
16 which are recordable over the nerve or from an innervated muscle. With this technique,  
17 responses are measured between two sites of stimulation, or between a stimulus and a  
18 recording site. Recording of the electrical response to stimulation of the nerve between  
19 these points along its route is conducted and compared to normal responses. The study  
20 measures speed (conduction velocity and/or latency), amplitude (size) and the shape of  
21 neurologic response for detecting demyelination and axon loss.  
22

23  
24 Nerve conduction studies are of two general types: sensory and motor. Either surface or  
25 needle electrodes can be used to stimulate the nerve or record the response. Axonal damage  
26 or dysfunction generally results in loss of nerve or muscle potential response amplitude;  
27 whereas demyelination leads to prolongation of conduction time and slowing of conduction  
28 velocity.  
29

30 Obtaining and interpreting NCS results requires extensive interaction between the  
31 performing qualified health care professional and patient and is most effective when both  
32 obtaining raw data and interpretation are performed concurrently on a real-time basis.  
33 Results of the NCS reflect on the integrity and function of:

- 34 • The myelin sheath (Schwann cell derived insulation covering an axon)
- 35 • The axon (an extension of neuronal cell body) of a nerve

36  
37 Interruption of axon and dysfunction of myelin will both affect NCS results. It is often also  
38 valuable to test conduction status in proximal segments of peripheral nerves. The  
39 stimulation of nerves is similar across all NCSs; the characteristics of motor, sensory, and  
40 mixed NCSs are different and are discussed separately below. In each case, an appropriate  
41 nerve is stimulated, and recording is made either from the appropriate nerves or from  
42 muscle supplied by the motor nerve.



1 Motor NCSs are performed by applying electrical stimulation at various points along the  
2 course of a motor nerve while recording the electrical response from an appropriate muscle.  
3 Response parameters include amplitude, latency, configuration, and motor conduction  
4 velocity.

5  
6 Sensory NCSs are performed by applying electrical stimulation near a nerve and recording  
7 the response from a distant site along the nerve. Response parameters include amplitude,  
8 latency, and configuration.

9  
10 Mixed NCSs are performed by applying electrical stimulation near a nerve containing both  
11 motor and sensory fibers (a mixed nerve) and recording from a different location along that  
12 nerve that also contains both motor and sensory nerve fibers. Response parameters include  
13 amplitude, latency, configuration, and motor conduction velocity."

14  
15 Electromyography (EMG) is the study and recording of intrinsic electrical properties of  
16 skeletal muscles. This is carried out with a needle electrode. Generally, the needles are of  
17 two types: monopolar or concentric. EMG is undertaken together with NCS. Unlike NCS,  
18 however, EMG testing relies on both auditory and visual feedback to the  
19 electromyographer. This testing is also invasive in that it requires needle electrode insertion  
20 and adjustment at multiple sites, and at times anatomically critical sites. As in NCS during  
21 EMG studies the electromyographer depends on ongoing real-time interpretation-based  
22 knowledge of clinical diagnosis being evaluated to decide whether to continue, modify, or  
23 conclude a test. This process requires knowledge of anatomy, physiology, and  
24 neuromuscular diseases.

25  
26 EMG results reflect not only on the integrity of the functioning connection between a nerve  
27 and its innervated muscle but also on the integrity of a muscle itself. The axon innervating  
28 a muscle is primarily responsible for the muscle's volitional contraction, survival, and  
29 trophic functions. Thus, interruption of the axon will alter the EMG. A few prime examples  
30 of conditions in which EMG is potentially helpful are disc disease producing spinal nerve  
31 dysfunction, advanced nerve compression in peripheral lesions, Amyotrophic Lateral  
32 Sclerosis (ALS), polyneuropathy, etc. After an acute neurogenic lesion, EMG changes may  
33 not appear for several days to weeks in the innervated muscles. Primary muscle disease  
34 such as polymyositis will also alter a normal EMG pattern. Myotonic disorders may show  
35 a pattern of spontaneous repetitive discharges on needle exploration.

36  
37 NCS are generally performed with needle electromyogram (NEMG), enabling the presence  
38 and extent of peripheral nerve pathology to be determined (Katirji, 2002; North American  
39 Spine Society [NASS], 2003; Aminoff, 2003; Asbury, 2004; AANEM 2016). EMG studies  
40 measure the electrical activity of muscles. When performed together, they can be extremely  
41 helpful in detecting whether the pathology originates in the proximal or distal root ganglia  
42 and whether the neuromuscular dysfunction relates to peripheral nerve disease.

1 Both EMGs and NCSs are required for a clinical diagnosis of peripheral nervous system  
2 disorders. EMG results reflect on the integrity of the functioning connection between a  
3 nerve and its innervated muscle and also on the integrity of a muscle itself. Performance of  
4 one does not eliminate the need for the other. Without awareness of the patterns of  
5 abnormality expected in different diseases and knowledge that the results of nerve  
6 conduction studies and electromyography may be similar in different diseases, diagnosis  
7 solely by EMG-NCS findings may be both inadequate and ultimately be detrimental to the  
8 patient. For example, EMG-NCS findings may overlap in the following pairs of disorders:  
9 inflammatory myopathies and ALS, ALS and multi-level radiculopathies, myotonia of  
10 channelopathies (periodic paralyses) and myotonic dystrophies, focal neuropathies as  
11 Carpal Tunnel Syndrome and proximal plexopathies. Other instances where knowledge of  
12 disease behavior is crucial are Chronic Inflammatory Demyelinating Neuropathy (CIDP)  
13 and Multifocal Motor Neuropathy. These entities display electrodiagnostic features that  
14 resemble generalized polyneuropathies. Neuromuscular transmission disorders require  
15 separation based on clinical presentation and electrical features.

16  
17 Without awareness of the disease spectrum, diagnosis solely by EMG-NCS findings may  
18 be either wrong or detrimental to the patient. Nerve conduction studies performed  
19 independent of needle electromyography (EMG) may only provide a portion of the  
20 information needed to diagnose muscle, nerve root, and most nerve disorders. When the  
21 nerve conduction study (NCS) is used on its own without integrating needle EMG findings  
22 or when an individual relies solely on a review of NCS data, the results can be misleading,  
23 and important diagnoses may be missed. For example, radiculopathies cannot be  
24 definitively diagnosed by NCS alone; EMG is performed to confirm the radiculopathy.  
25 According to the American Academy of Neurology (AAN), needle EMG (NEMG), in  
26 combination with nerve conduction studies, is the gold standard methodology for assessing  
27 the neurophysiologic characteristics of neuromuscular diseases (Pullman et al., 2000). In  
28 summary, axonal and muscle involvement are most sensitively detected by EMGs, and  
29 myelin and axonal involvement are best detected by NCSs.

30  
31 EMG should always be performed by a physician or health care provider who is specially  
32 trained in electrodiagnostic medicine (neurologist, physiatrist, clinical neurophysiologist,  
33 board-certified physical therapist) with real-time interpretation (performed only by a  
34 physician) and is part of the complete electrodiagnostic examination (AANEM, 2022).  
35 EMG reports should include documentation of the muscle tested, the presence and type of  
36 spontaneous activity and the characteristics of the voluntary unit potentials.

1 NCS may be performed by a trained technologist under the direct supervision of a  
2 physician. Direct supervision implies that a physician is in close proximity to the patient  
3 undergoing testing, is immediately available to provide the trained technician with  
4 assistance and direction if necessary and is responsible for determining the nerve  
5 conduction studies that are appropriate. In general, a physician assesses the results of the  
6 degree of myelination or axonal loss.

### 7 8 **H-reflex/F-wave Testing**

9 Late response (H-reflex and F-wave testing) testing is a type of NCS usually performed on  
10 nerves more proximal to the spine. The H-reflex involves conduction from the periphery  
11 to and from the spinal cord. The H-reflex study involves the assessment of the  
12 gastrocnemius/soleus muscle complex in the calf and is usually performed bilaterally due  
13 to the need to assess symmetrical results in determining abnormalities. The F-wave study  
14 is a late response similar to the H-reflex. F-wave studies are used to assess the proximal  
15 segments of the motor nerve function and are performed in combination with the  
16 examination of motor nerves. Both studies are helpful in diagnosing conditions of  
17 radiculopathies, plexopathies, polyneuropathies, and proximal mononeuropathies  
18 (AANEM, 2022). Late response studies are additional studies complementary to NCV and  
19 are performed during the same patient evaluation.

20  
21 Single Fiber EMG: Single fiber EMG uses a very highly selective electrode that can focus  
22 on a restricted number of muscle fibers. It is utilized to study neuromuscular jitter and  
23 muscle fiber density. Fiber density may be increased in neuromuscular disorders such as  
24 myasthenia gravis. Jitter is a measure of variation in neuromuscular transmission times and  
25 may be increased in some neuromuscular disorders (Sanders, Howard, 2008; Barboi and  
26 Barkhaus, 2004; Sanders, 2004). Single fiber EMG has many uses; however, it is most  
27 useful to confirm diagnosis for disorders of the neuromuscular junction in suspected  
28 myasthenia gravis when other tests are inconclusive or negative (Sanders, Howard, 2008;  
29 Gooch and Pullman, 2004).

### 30 31 **Macro EMG**

32 Macro EMG is less selective when compared to standard NEMG or single-fiber EMG and  
33 is primarily used in investigational settings. It is a method of analyzing the motor unit  
34 quantitatively. A surface electrode is used for reference, and motor unit action potentials  
35 (MUAP) are measured from a macro needle. Authors suggest that macro EMG evaluates a  
36 large recording area compared to other needle electrodes and is considered representative  
37 of the entire MUAP area (Barboi and Barkhous, 2004).

### 38 39 **Surface EMG (SEMG)**

40 In contrast to NEMG, SEMG, also referred to as surface scanning EMG, is a noninvasive,  
41 computer-based technique that records the electrical impulses using electrodes placed on  
42 the surface of the skin overlying the nerve at rest (i.e., static) and during activity (i.e.,

1 dynamic). The procedure studies the topography of the motor unit action potential  
 2 (MUAP) and is assessed by computer analysis of the frequency spectrum, amplitude, or  
 3 root mean square of the electrical action potential. The SEMG differs from the NEMG  
 4 with respect to technical requirements and electrical properties. SEMG electrodes  
 5 measure from a wide area of muscle, have a relatively narrow frequency band (range 20  
 6 to 500 Hz), have low-signal resolution, and are highly susceptible to movement artifact  
 7 (Pullman, 2000). The proposed use for this type of EMG is to aid in the diagnosis of  
 8 neuromuscular disorders and low back pain, and to aid in assessing the prognosis of  
 9 disorders involving muscle lesions. The technology has also been used to monitor  
 10 bruxism (i.e., grinding and clenching of teeth). The electrical activity of muscle may be  
 11 recorded with surface EMG, although spontaneous electrical activity and voluntary motor  
 12 units cannot be (Lange and Trojaborg, 2000). Although not widely used as a diagnostic  
 13 tool, high-density SEMG (HD-sEMG) is a multichannel SEMG that records the input of  
 14 multiple electrodes placed on one muscle and is being studied as a possible method of  
 15 detecting single MU characteristics (Drost et al., 2006). Nonetheless, the clinical utility  
 16 of surface EMG testing outside of the investigative setting has not been proven in the  
 17 peer-reviewed scientific literature.

### 18 **Paraspinal EMG**

19 Paraspinal EMG scanning, a type of SEMG, also referred to as paraspinal SEMG, has been  
 20 investigated as a method of assessing the paraspinal muscles of patients which provide  
 21 support to the spinal column. Impairment of the paraspinal muscles may lead to abnormal  
 22 motion and pain. The paraspinal SEMG is performed using a single electrode or an array  
 23 of electrodes placed on the skin surface with recordings that are typically made at rest, in  
 24 various positions, or after physical activity. The diagnostic utility of paraspinal EMG is not  
 25 known, and its role in patient management has not been established.

### 26 **Somatosensory Evoked Potentials (SEPs)**

27 SEPs are an extension of the electrodiagnostic evaluation and can be used to test  
 28 conduction in various sensory fibers of the peripheral and central nervous systems. SEPs  
 29 may be used to assess the functional integrity of the central and peripheral sensory  
 30 pathways. SEPs are noninvasive studies performed by repetitive submaximal stimulation  
 31 of a sensory or mixed sensorimotor peripheral nerve and recording the averaged responses  
 32 from electrodes placed over proximal portions of the nerve stimulated, plexus, spine, and  
 33 scalp (AANEM, 2015). SSEPs are an extension of the electrodiagnostic evaluation and are  
 34 used to evaluate nerves that cannot be studied by conventional nerve conduction studies,  
 35 including electromyography. SEPs are typically elicited by stimulating mixed nerves  
 36 (median, ulnar, tibial, and peroneal) to assess sensory pathways. Therefore, the application  
 37 of standard SEPs to study radicular disease is necessarily limited to investigating the  
 38 lumbar and cervical regions because of the limited number of sites to stimulate (AAN,  
 39 1997).  
 40  
 41

1 The evoked potential response depends on the functional integrity of the nerve that is  
2 stimulated. An abnormal SSEP points to a problem in the nerve conduction mechanism  
3 that carries the impulse to the brain, however, the SSEP abnormality is not disease  
4 specific—an abnormal SSEP indicates impairments associated with certain disorders. An  
5 abnormal SSEP signifies an impaired pathway, helps to localize it, and provides a  
6 prognostic guide. The SSEP does not provide any indication about the nature of the  
7 underlying pathological processes. Although evoked potentials offer additional  
8 information regarding function that can be clinically useful, magnetic resonance imaging  
9 (MRI) is often the preferred test to determine structural abnormalities and provides more  
10 specific information regarding neurologic structures.

11  
12 SSEPs are altered by impairment of the somatosensory pathway which may occur as a  
13 result of both diffuse (e.g., diseases of myelin, hereditary system degenerations, coma) or  
14 local disorders (e.g., tumors, vascular lesions). SSEP abnormalities can be detected in a  
15 variety of different settings; therefore, the electrophysiologic findings should be interpreted  
16 in the clinical context in which they are obtained (e.g., assessing functional integrity,  
17 diagnostic purposes, determining the course of neurological disorders, determining  
18 pathological involvement). SSEPS are helpful in evaluating ill-defined complaints. A  
19 physician assesses the patient and determines a preliminary differential diagnosis; SSEP  
20 testing may then be performed by a trained technologist under the direct supervision of a  
21 trained electrodiagnostic physician. Direct supervision implies that a physician is in close  
22 proximity to the patient undergoing testing, is immediately available to provide the trained  
23 technician with assistance and direction if necessary and is responsible for determining the  
24 SSEP studies that are appropriate.

25  
26 Evoked potentials are used to assist in diagnosing ill-defined neurological conditions and  
27 to categorize afferent pathways that may be responsible for the resulting symptoms  
28 experienced by the patient. Conditions for which SSEPS may offer clinical utility include  
29 (American Association of Neuromuscular and Electrodiagnostic Medicine [AANEM],  
30 2015):

- 31 • Spinal cord trauma
- 32 • Subacute combined degeneration
- 33 • Non-traumatic spinal cord lesions (e.g., cervical spondylosis)
- 34 • Multiple sclerosis
- 35 • Spinocerebellar degeneration
- 36 • Myoclonus
- 37 • Coma

38  
39 SSEPs have been utilized to evaluate other peripheral nerve disorders such as acute  
40 inflammatory demyelinating polyradiculoneuropathy and focal neuropathies (e.g.,  
41 entrapment neuropathies, carpal tunnel syndrome, lateral femoral cutaneous neuropathy,  
42 medial and lateral plantar neuropathy, saphenous neuropathy, intercostals neuropathy,

1 trigeminal neuropathy, plexopathy) in addition to nerve root dysfunction (i.e., lumbosacral  
2 root [acute radiculopathies], thoracic root, cervical root). However, the diagnostic utility  
3 of SSEPs for these conditions remains controversial (AANEM, 2015). The AANEM  
4 reported that the available evidence is not convincing that SSEPs for these indications  
5 provide information that cannot be obtained with conventional nerve conduction studies or  
6 needle electromyography. SSEPs are rarely used to assess peripheral neuropathy as  
7 standard nerve conduction velocity studies are the preferred test. There are no data to  
8 suggest a role for SSEPs in the evaluation of behavioral health disorders. The usefulness  
9 of evoked potential testing in psychiatry, including SSEPs, is still under investigation  
10 (Guse and Love, 2005). Recordings of SSEP can be normal even in patients with extreme  
11 sensory deficits due to the presence of multiple parallel, afferent somatosensory pathways.  
12 This procedure is often performed to investigate patients with multiple sclerosis (MS);  
13 various coma states, such as those from post-traumatic injury or post-anoxia; suspected  
14 brain death; and to indicate the extensiveness of lesion damage in spinal cord injuries. The  
15 return or presence of a cortically-generated response to stimulation of a nerve below the  
16 injured portion of the cord indicates an incomplete lesion and therefore may offer a better  
17 prognosis. SSEP testing is typically performed bilaterally. Depending on the clinical  
18 situation being investigated, several nerves in one extremity may have to be tested and  
19 compared with the opposite limb. The physician's SSEP report should indicate which  
20 nerves were tested, latencies at various testing points and an evaluation of whether the  
21 results were normal or abnormal.

### 22 23 **Neuromuscular Junction Testing**

24 The neuromuscular unit is made up of four components: the anterior horn cells of the spinal  
25 cord, the peripheral nerve, the neuromuscular junction, and the muscle being innervated.  
26 The level of disease determines the signs and symptoms an individual develops.  
27 Neuromuscular junction testing involves the stimulation of an individual motor nerve by  
28 means of repetitive electrical impulses with measurement of the resulting electrical activity  
29 of a muscle supplied by that nerve. Supramaximal electrical stimuli are delivered to the  
30 nerve. A surface electrode over, or percutaneous electrode placed in, a corresponding  
31 muscle records the evoked muscle action potentials using standard nerve conduction study  
32 techniques. The nerve is then stimulated electrically in a repetitive train at 2-3 Hz, or in  
33 special circumstances at higher rates up to 50 Hz. Testing may be performed in addition to  
34 NCS of the same nerves and/or EMG. In diseases of the neuromuscular junction,  
35 characteristic changes of a progressive decrease (decrement) in the compound action  
36 potential amplitude may be seen during the repetitive stimulation. Testing is indicated for  
37 suspected diseases of the neuromuscular junction (generally associated with progressive  
38 motor fatigability) which include myopathy, focal neuropathy, myasthenia gravis and  
39 Lambert Eaton myasthenic syndrome. Another condition that testing may be indicated for,  
40 botulism, is associated with a decrease in the amount of acetylcholine released, and results  
41 in weakness (Juel, 2012; Shearer, Jagoda, 2009).

## 1 **Automated Nerve Conduction Testing**

2 Proponents of automated nerve conduction tests suggest that they can be used in a variety  
 3 of clinical settings, including a physician’s office, without the need for specialized training  
 4 or equipment, theoretically obtaining results within minutes. Portable, automated devices  
 5 have been developed to provide nerve conduction studies at the point of care (e.g., primary  
 6 care setting), particularly for carpal tunnel evaluation and evaluation of diabetic peripheral  
 7 neuropathy, as an alternative to or as an adjunct to other conventional testing methods.  
 8 Manufacturers state these devices have computational algorithms, provide delivery of  
 9 stimulus, measure and analyze the patient’s response, and provide a detailed report of study  
 10 results.

11  
 12 The NC-stat System and ADVANCE™ NCS system (NEUROMetrix® Inc., Waltham,  
 13 MA) are hand-held, noninvasive, automated nerve conduction testing systems that have  
 14 been proposed as an alternative to conventional nerve conduction testing. The devices have  
 15 been marketed for use in an office or clinic setting, to assess nerves of the upper and lower  
 16 extremities assisting in the diagnosis of peripheral nerve disorders such as carpal tunnel  
 17 syndrome, diabetic peripheral neuropathy, and sciatica. The manufacturer suggests that  
 18 data can be analyzed and readily available within minutes and then transmitted to the  
 19 physician via email, internet or as a faxed document. A computerized system interprets the  
 20 data. The proposed benefits of these devices are ease of use and rapid results.

21  
 22 Another device proposed for automated testing of peripheral nerves is the Brevio nerve  
 23 conduction monitoring system (Neurotron Medical, Inc., West Trenton, NJ). According to  
 24 the manufacturer, the device calculates latency and amplitude for sensory, motor, and f-  
 25 wave responses using a single noninvasive neuro-sensor for testing performed on the  
 26 patient. Similar to the NC-stat device, when testing is performed, the results can be  
 27 immediately sent to a printer in the office or through a Web service for an electronic report.

## 28 29 **Electrodiagnostic Testing General Principles**

30 Electrodiagnostic testing of nerve function is established as having diagnostic utility and  
 31 is professionally recognized when such tests are ordered to clarify or confirm findings from  
 32 history and physical examination including a neurological examination as described within  
 33 this guideline. Current guidelines do not support the use of these tests for initial or routine  
 34 screening of patients in the absence of findings from physical examination or when the  
 35 results of such tests are unlikely to influence treatment planning or patient management.

36  
 37 In order to establish the necessity for special diagnostic testing, one needs to consider at  
 38 least the following:

- 39 • Is there historical or chief complaint information that suggests a condition or lesion  
 40 that can only be appropriately evaluated using special tests or was an appropriate  
 41 physical examination performed that brought forth findings suggestive of a  
 42 condition or lesion that can only be appropriately evaluated using special tests?

- 1 • For nerve function tests specifically, was a neurological examination of reflexes,  
2 sensory integrity, and motor function performed as part of the physical examination  
3 and were findings indicative of nerve insult (diminished reflexes, dermatome-  
4 specific sensory deficits, or nerve-root-specific muscle weakness)?
- 5 • Would the anticipated information or clarification from the results of the special  
6 tests influence treatment planning?
- 7 • If there is a strong indication for special testing because of suspicious findings on  
8 history or physical examination, would positive findings on special tests necessitate  
9 referral to a specialist where such testing might be repeated or duplicated;  
10 specifically, is the test most appropriately performed or ordered by the clinician  
11 evaluating the patient or by a specialist to whom the patient should be referred?  
12

13 When patients present with neck or low back pain with associated extremity complaints of  
14 pain, numbness, or tingling it is hoped that a pattern match can be made between these  
15 complaints and objective physical examination demonstration of sensory loss, motor loss,  
16 or an associated deep tendon reflex decrease. Use of provocative maneuvers such as  
17 compression, distraction, or percussive maneuvers (e.g., Cervical Compression Test,  
18 Straight Leg Raise, Tinel’s sign) may further clarify the diagnosis. Other sources of the  
19 complaint should also be evaluated including referral from trigger points or facet irritation.  
20 Management should be based on the suspected cause. Consideration of electrodiagnostic  
21 testing may be warranted when:

- 22 • The diagnosis and treatment plan are not confirmed by the history and physical  
23 examination;
- 24 • A preliminary diagnosis and trial of treatment are not resulting in improvement;
- 25 • The patient’s condition does not respond to treatment or worsens; or
- 26 • In order to make a proper diagnosis and treatment plan.  
27

28 However, in most cases, it would be appropriate to initiate conservative care (e.g., 4-6  
29 weeks), being sure to monitor for worsening or non-response to care, prior to utilizing  
30 invasive electrodiagnostic procedures . The electrodiagnostic evaluation is an extension of  
31 the neurologic portion of the physical examination. Both require a detailed knowledge of  
32 a patient and their disease. The electrodiagnostic consultation provides useful information  
33 in the evaluation of motor, sensory and autonomic neurons, nerve roots, brachial and  
34 lumbar plexi, peripheral nerves, neuromuscular junction, and muscles. Electrodiagnostic  
35 studies should enhance, but not replace, a careful history and physical examination.  
36 Training in the performance of electrodiagnostic procedures in isolation of knowledge  
37 about clinical diagnostic and management aspects of neuromuscular diseases, may not be  
38 adequate for proper performance of an electrodiagnostic evaluation and correct  
39 interpretation of electrodiagnostic test results.



1 The broad diagnostic scope of NCS is recognizable by the foregoing description. There  
2 may be instances where questions about an indication, or need for a study, will arise. The  
3 clinical history and examination, carried out before the study, must always describe and  
4 document clearly and comprehensibly the need for the planned test. A "rule-out" diagnosis  
5 is typically not acceptable. Often, pain, paresthesia, or weakness in an extremity is the  
6 reason for an NCS or EMG. These common symptoms result not only from axonal and  
7 myelin dysfunction but also from systemic, non-neurological illnesses. EMG and NCV  
8 may help in making this distinction. Therefore, symptom-based diagnoses such as "pain in  
9 limb" weakness, disturbance in skin sensation or "paresthesia" are acceptable provided the  
10 clinical assessment unequivocally supports the need for a study. To cite but one example  
11 of many, an EMG or NCS is irrelevant as a first order diagnostic test for limb pain resulting  
12 from immediate antecedent trauma or acute bone injury.

13  
14 The intensity and extent of testing with EMG and NCS are matters of clinical judgment  
15 developed after the initial pre-test evaluation, and later modified during the testing  
16 procedure. Decisions to continue, modify or conclude a test also rely on a knowledge base  
17 of anatomy, physiology, and neuromuscular diseases. There is a requirement for ongoing  
18 real-time clinical diagnostic evaluation, especially during EMG examination. Also, EMG  
19 examination is invasive. Needle placement in the exact muscle of interest is essential. It  
20 requires needle exploration near vital structures as the pleura, femoral neurovascular  
21 bundle, peritoneum, intraspinal spaces, carotid artery, orbit, and brachial plexus. Risk of  
22 infection from AIDS, Hepatitis B-E, Creutzfeldt-Jakob encephalopathy, and hemorrhage  
23 from anticoagulation can be managed by proper techniques. Needle EMG is relatively  
24 contraindicated in persons on anti-coagulant therapy with coumadin (Warfarin) or heparins  
25 that cannot be interrupted. Oh (2003) observed that patients with a variety of bleeding  
26 disorders may be referred for needle EMG. Oh (2003) recommended that the referring  
27 physician and the electromyographer examine each case individually, carefully weighing  
28 the potential risks and benefits. Cardiac pacemakers and implanted cardiac defibrillators  
29 (ICDs) are increasingly used in clinical practice, and no evidence exists indicating that  
30 performing routine electrodiagnostic studies on patients with these devices poses a safety  
31 hazard. However, there are theoretical concerns that electrical impulses of nerve  
32 conduction studies (NCSs) could be erroneously sensed by devices and result in unintended  
33 inhibition or triggering of output or reprogramming of the device (Schoeck, 2007). In  
34 general, the closer the stimulation site is to the pacemaker and pacing leads, the greater the  
35 chance for inducing a voltage of sufficient amplitude to inhibit the pacemaker. Despite  
36 such concerns, no immediate or delayed adverse effects have been reported with routine  
37 NCS (AANEM, 2014).

38  
39 In patients with external cardiac pacemakers, the conductive lead, inserted into the heart  
40 (usually transvenously) and connected to the external cardiac pacemaker, presents a serious  
41 potential hazard of electric injury to the heart (Al-Shekhlee et al., 2003). NCSs are not

1 recommended in any patient with an external conductive lead terminating in or near the  
2 heart.

3  
4 The nature of recurrent and frequent electrical impulses that may occur with repetitive  
5 stimulation or eliciting somatosensory evoked potentials (SEP) pose a special  
6 circumstance. Nerve stimulation in the lower extremities or in distal upper extremities  
7 would be unlikely to have untoward effects upon pacemakers or ICDs. Repetitive  
8 stimulation for assessing integrity of the neuromuscular junction typically necessitates  
9 study of proximal and/or cranial nerve-innervated muscles, which may place the  
10 stimulating electrode closer to the cardiac device. Nonetheless, as there are no data to  
11 determine the safety of performing these procedures in patients with pacemakers or ICDs,  
12 proximal upper extremity and cranial nerve stimulation sites should be avoided for  
13 repetitive and SEP stimulation (AANEM, 2014).

14  
15 Needle EMG recording does not introduce electrical current into the body and, therefore,  
16 poses no risk of interference with implanted cardiac devices.

17  
18 No known contraindications exist from performing needle EMG and NCSs on pregnant  
19 patients. In addition, no complications from these procedures have been reported in the  
20 literature. Evoked response testing, likewise, has not been reported to cause any problems  
21 when performed during pregnancy (AANEM, 2014).

22  
23 The minimum standards recommended by the AANEM for electrodiagnostic testing  
24 (EDX) include the following:

- 25 1. EDX testing should be medically indicated.
- 26 2. Testing should be performed using EDX equipment that provides assessment of all  
27 parameters of the recorded signals. Studies performed with devices designed only  
28 for “screening purposes” rather than diagnosis are not acceptable.
- 29 3. The number of tests performed should be the minimum needed to establish an  
30 accurate diagnosis.
- 31 4. NCSs should be either (a) performed directly by a physician or (b) performed by a  
32 trained individual under the direct supervision of a physician. Direct supervision  
33 means that the physician is in close physical proximity to the EDX laboratory while  
34 testing is underway, is immediately available to provide the trained individual with  
35 assistance and direction and is responsible for selecting the appropriate NCSs to be  
36 performed.
- 37 5. The needle EMG examination must be performed by a physician specially trained  
38 in EDX medicine, as these tests are simultaneously performed and interpreted. The  
39 EDX laboratory must have the ability to perform needle EMG. The needle EMG  
40 must include evaluation of both resting and voluntary activities. NCSs should not  
41 be performed without needle EMG except in unique circumstances. EMG and  
42 NCSs should be performed together in the same EDX evaluation when possible.

- 1       6. It is appropriate for only 1 attending physician to perform or supervise all of the  
2 components of the EDX testing (e.g., history taking, physical evaluation,  
3 supervision and/or performance of the EDX test, and interpretation) for a given  
4 patient and for all the testing to occur on the same date of service. The reporting of  
5 NCS and needle EMG study results should be integrated into a unifying diagnostic  
6 impression.
- 7       7. In contrast, dissociation of NCS and needle EMG results into separate reports is  
8 inappropriate unless specifically explained by the physician. Performance and/or  
9 interpretation of NCSs separately from that of the needle EMG component of the  
10 test should clearly be the exception (e.g., when testing an acute nerve injury) rather  
11 than an established practice pattern for a given practitioner.

12  
13 In a position statement published by the AANEM regarding the performance and  
14 interpretation of electrodiagnostic studies (AANEM, 2020), the AANEM states, “To reach  
15 a diagnosis based on EDX testing, it is imperative that the physician has obtained a history  
16 and examined the patient and designed the NCSs and EMG testing based on the  
17 information obtained from the patient. Using a predetermined or standardized battery of  
18 NCSs for all patients is inappropriate because it may be possible to obtain the data needed  
19 to reach a diagnosis with fewer studies. Alternatively, a pre-determined battery may not  
20 include the appropriate NCSs and/or EMG tests to determine the diagnosis. If the EDX  
21 studies are not based on the patient’s history and physical examination findings,  
22 substandard care is being provided. If the NCS results a physician is relying on are  
23 interpreted offsite without integrating information from the needle EMG, substandard care  
24 is being provided. It is the opinion of the AANEM that relying on NCSs alone to make  
25 health care decisions is usually inadequate and inappropriate.”

26  
27 Except in limited clinical situations, performing nerve conduction studies (NCS) together  
28 with needle electromyography (NEMG) is required to diagnose peripheral nervous system  
29 disorders. According to the AANEM circumstances under which NCS and EMG should  
30 not be performed together include, but are not limited to, limited follow-up studies of  
31 neuromuscular structures that have undergone previous electrodiagnostic evaluation, the  
32 current use of anticoagulants, or the presence of lymphedema. In addition, the AANEM  
33 indicates that for suspected carpal tunnel syndrome, the extent of the needle EMG  
34 examination depends on the results of the NCSs and the differential diagnosis considered  
35 for the individual patient (AANEM, 2022). The AANEM (2022) does not support  
36 screening testing, monitoring disease intensity, or monitoring of treatment efficacy for  
37 polyneuropathy of diabetes or polyneuropathy of end stage renal disease (ESRD). NEMG  
38 is also not recommended for any of the following:

- 39       • Testing of intrinsic foot muscles in the diagnosis of proximal lesions  
40       • Definitive diagnostic conclusion from paraspinal EMG in regions bearing scars of  
41 previous surgeries, such as previous laminectomy

- 1 • Pattern setting limited limb muscle examinations without paraspinal muscle
- 2 testing for diagnosis of radiculopathy
- 3 • Needle EMG testing performed shortly after trauma
- 4

5 **Number of Services Recommended:** Table 1 summarizes the recommendations of the  
 6 AANEM regarding the reasonable maximum number of studies per diagnostic category  
 7 necessary for a physician to arrive at a diagnosis for 90% of patients with that final  
 8 diagnosis, within a 12-month timeframe (AANEM, 2022).

9  
 10 **Table 1. Number of Services Recommended:**

	<b>Limbs Studied by Needle Electromyography (95860-95864, 95867-95870, 95885-95887)</b>	<b>Nerve Conduction Studies (Total nerve studied, 95907- 95913)</b>	<b>Neuromuscular Junction Testing (Repetitive Stimulation)</b>
<b>Indication</b>	<b>Number of Services (Tests)</b>	<b>Number of Services (Tests)</b>	<b>Number of Services (Tests)</b>
Carpal Tunnel (unilateral)	1	7	--
Carpal Tunnel (bilateral)	2	10	--
Radiculopathy	2	7	--
Mononeuropathy	1	8	--
Polyneuropathy/ Mononeuropathy Multiplex	3	10	--
Myopathy	2	4	2
Motor Neuronopathy (e.g., ALS)	4	6	2

<b>Limbs Studied by Needle Electromyography (95860-95864, 95867-95870, 95885-95887)</b>			
		<b>Nerve Conduction Studies (Total nerve studied, 95907-95913)</b>	<b>Neuromuscular Junction Testing (Repetitive Stimulation)</b>
<b>Indication</b>	<b>Number of Services (Tests)</b>	<b>Number of Services (Tests)</b>	<b>Number of Services (Tests)</b>
Plexopathy	2	12	--
Neuromuscular Junction	2	2	3
Tarsal Tunnel Syndrome (unilateral)	1	8	--
Tarsal Tunnel Syndrome (bilateral)	2	11	--
Weakness, Fatigue, Cramps, or Twitching (focal)	2	7	2
Weakness, Fatigue, Cramps, or Twitching (general)	4	8	2
Pain, Numbness, or Tingling (unilateral)	1	9	--
Pain, Numbness, or Tingling (bilateral)	2	12	--

### 1 **Carpal Tunnel Syndrome**

2 For suspected carpal tunnel syndrome (CTS), bilateral median motor and sensory NCSs  
 3 are often indicated. The studies in the contralateral asymptomatic limb serve as controls in  
 4 cases where values are borderline and may establish the presence of bilateral CTS. Two to  
 5 4 additional sensory or mixed NCSs can be compared to the median sensory NCSs to  
 6 increase the diagnostic sensitivity of the testing. The additional sensory NCSs and an  
 7 additional motor NCS (usually ulnar) are indicated to exclude a generalized neuropathy or  
 8 multiple mononeuropathies. If 2 sensitive sensory NCSs are performed at the beginning  
 9 start, additional sensory testing on the same limb is rarely needed. For suspected bilateral  
 10 CTS, bilateral median motor and sensory NCSs are indicated. Up to 2 additional motor and  
 11 2 additional sensory NCSs are often indicated. The extent of the needle EMG examination  
 12 depends on the results of the NCSs and the differential diagnosis considered in the  
 13 individual patient. Additional testing may be indicated in patients with a differential  
 14 diagnosis which includes peripheral neuropathy, cervical radiculopathy, brachial  
 15 plexopathy, or more proximal median neuropathy.

### 16 **Radiculopathy**

17 A minimal evaluation for radiculopathy includes 1 motor and 1 sensory NCS and a needle  
 18 EMG examination of the involved limb. However, the EDX testing can include up to 3  
 19 motor NCSs (in cases of an abnormal motor NCS, the same nerve in the contralateral limb  
 20 and another motor nerve in the ipsilateral limb can be studied) and 2 sensory NCSs.  
 21 Bilateral studies are often necessary to exclude a central disc herniation with bilateral  
 22 radiculopathies or spinal stenosis or to differentiate between radiculopathy and plexopathy,  
 23 polyneuropathy, or mononeuropathy. H reflexes and F waves may provide useful  
 24 complementary information and assist in confirmation of root dysfunction. Radiculopathies  
 25 cannot be diagnosed by NCS alone; needle EMG must be performed to confirm a  
 26 radiculopathy. Therefore, these studies should be performed together by 1  
 27 physician/qualified health care practitioner supervising and/or performing all aspects of the  
 28 study.  
 29

### 30 **Polyneuropathy/Mononeuropathy Multiplex**

31 In order to characterize the nature of the polyneuropathy (axonal or demyelinating, diffuse  
 32 or multifocal) and in order to exclude polyradiculopathy, plexopathy, neuronopathy, or  
 33 multiple mononeuropathies, it may be necessary to study 4 motor and 4 sensory nerves,  
 34 consisting of 2 motor and 2 sensory NCSs in 1 leg, 1 motor and 1 sensory NCS in the  
 35 opposite leg, and 1 motor and 1 sensory NCS in 1 arm. H-reflex studies and F-wave studies  
 36 from 2 nerves may provide additional diagnostic information. At least 2 limbs should be  
 37 studied by a needle EMG examination. Studies of related paraspinal muscles are indicated  
 38 to exclude some conditions such as polyradiculopathy.  
 39

**Myopathy**

To diagnose a myopathy, a needle EMG examination of 2 limbs is indicated. To help exclude other disorders such as polyneuropathy or neuronopathy, 2 motor and 2 sensory NCSs are indicated. Two repetitive motor nerve stimulation studies may be performed to exclude a disorder of NM transmission.

**Motor Neuronopathy**

In order to establish the diagnosis of motor neuronopathy (e.g., amyotrophic lateral sclerosis and to exclude other disorders in the differential diagnosis, such as multifocal motor neuropathy or polyneuropathy, up to 4 motor nerves and 2 sensory nerves may be studied. Needle EMG of up to 4 extremities (or 3 limbs and facial or tongue muscles) is often necessary to document widespread denervation and to exclude a myopathy. One repetitive motor nerve stimulation study may be indicated to exclude a disorder affecting NMJ transmission.

**Plexopathy**

To characterize a brachial plexopathy and differentiate it from cervical radiculopathy and mononeuropathies it may be necessary to perform additional sensory studies (e.g., medial, and lateral antebrachial cutaneous nerves) for a total of up to 6 sensory studies. It may also be necessary to perform up to 4 motor studies.

To characterize a lumbosacral plexopathy and differentiate it from lumbosacral radiculopathy, mononeuropathies and polyneuropathy, it may be necessary to perform up to 4 sensory studies, up to 4 motor studies and up to 2 H-reflex studies.

For both brachial and lumbosacral plexopathies, up to 2 additional studies (sensory and/or motor) may be performed in the contralateral (at times asymptomatic) limb to better definite the diagnosis.

**Neuromuscular Junction**

To demonstrate and characterize abnormal NMJ transmission, repetitive nerve stimulation studies should be performed in up to 3 nerves and single fiber EMG (SFEMG) in up to 2 muscles. If any of these are abnormal, up to 2 motor and 2 sensory NCSs may be performed to exclude neuropathies that can be associated with abnormal NM transmission. At least 1 motor and 1 sensory NCS should be performed in a clinically involved limb, preferably in the distribution of a nerve studied with repetitive stimulation or SFEMG. At least 1 distal and 1 proximal muscle should be studied by a needle EMG examination to exclude a neuropathy or myopathy that can be associated with abnormal repetitive stimulation studies or SFEMG. At least 1 of the muscles should be clinically involved and both muscles should be in clinically involved limbs.

1 In combination, NCSs and a needle EMG examination may be most helpful when  
 2 performed several weeks after the injury has occurred. However, NCSs are often useful  
 3 acutely after nerve injury, for example, if there is concern that a nerve has been severed. In  
 4 fact, if studies are delayed, the opportunity to precisely identify the region of injury or to  
 5 intervene may be lost. In some cases, even needle EMG testing performed immediately  
 6 after a nerve injury may demonstrate abnormal motor unit action potential (MUAP)  
 7 recruitment and/or provide information that can be helpful to document preexisting  
 8 conditions, date the injury, or serve as a baseline for comparison with later studies.

9  
 10 Because of the variability of different nerve injuries, a standard rule on the timing of EDX  
 11 testing cannot easily be established, and the AANEM does not have specific  
 12 recommendations in this regard. In all instances, the AANEM encourages dialogue  
 13 between physicians and payers, and encourages the appropriate use of the physician's  
 14 clinical judgment in determining when studies are most appropriately performed and what  
 15 studies should be conducted.

### 16 **Frequency of Electrodiagnostic Testing in a Given Patient**

17 There are many clinical situations where good medical management requires repeat testing,  
 18 such as in the following examples:

- 19 1. Second diagnosis. Where a single diagnosis is made on the first visit, but the patient  
 20 subsequently develops a new set of symptoms, further evaluation is required for a  
 21 second diagnosis before treatment can begin.
- 22 2. Inconclusive diagnosis. When a serious diagnosis (e.g., ALS) is suspected but the  
 23 results of the needle EMG/NCS examination are insufficient to be conclusive,  
 24 follow-up studies are needed to establish or exclude the diagnosis.
- 25 3. Rapidly evolving disease. Initial EDX testing in some diseases may not show any  
 26 abnormality (e.g., Guillain-Barré syndrome) in the first 1 to 2 weeks. An early  
 27 diagnosis confirmed by repeat electrodiagnosis must be made quickly so treatment  
 28 can begin. Follow-up testing can be extremely useful in establishing prognosis and  
 29 monitoring patient status.
- 30 4. Course of the disease. Certain treatable diseases such as polymyositis and  
 31 myasthenia gravis follow a fluctuating course with variable response to treatment.  
 32 The physician treating such patients needs to monitor the disease progress and the  
 33 response to therapeutic interventions. The results of follow-up evaluations may be  
 34 necessary to guide treatment decisions.
- 35 5. Unexpected disease course. In certain situations, management of a diagnosed  
 36 condition may not yield expected results or new, questionably related problems  
 37 may occur (e.g., failure to improve following surgery for radiculopathy). In these  
 38 instances, reexamination is appropriate.
- 39



- 1       6. Recovery from injury. Repeat evaluations may be needed to monitor recovery, to  
2       help establish prognosis, and/or to determine the need for and timing of surgical  
3       intervention (e.g., traumatic nerve injury), and to assess recovery over time  
4       following peripheral nerve surgery.

5  
6       Repeat EDX evaluation is, therefore, sometimes necessary and, when justifiable, should be  
7       reimbursed. Reasonable limits can be set concerning the frequency of repeat EDX testing  
8       per year in a given patient by a given EDX evaluation for a given diagnosis. The following  
9       numbers of tests per 12-month period per diagnosis per physician are acceptable:

- 10  
11       1. Two tests for carpal tunnel-unilateral, carpal tunnel-bilateral, radiculopathy,  
12       mononeuropathy, polyneuropathy, myopathy, and neuromuscular junction (NMJ)  
13       disorders.  
14       2. Three tests for motor neuronopathy, plexopathy, acute inflammatory demyelinating  
15       polyradiculoneuropathy/Guillain Barré Syndrome (AIDP/GBS) and following  
16       peripheral nerve surgery.

17  
18       These limits should not apply if the patient requires evaluation by more than 1 EDX  
19       physician (i.e., a second opinion or an expert opinion at a tertiary care center) in a given  
20       year or if the patient requires evaluation for a second diagnosis in a given year. Additional  
21       studies then may be required or appropriate above these guidelines. In such situations, the  
22       reason for the repeat study should be included in the body of the report or in the patient's  
23       chart. Comparison with the previous test results should be documented. This additional  
24       documentation from the physician regarding the necessity for the additional repeat testing  
25       would be appropriate. Repeat EDX testing should not be necessary in a 12-month period  
26       in 80% of all cases.

27  
28       The Professional Practice Committee of the AANEM developed the following  
29       recommendations as part of the ABIM Choosing Wisely Initiative (AANEM, 2015):

- 30       • Don't do a needle electromyography (EMG) test for isolated neck or back pain after  
31       a motor vehicle accident, as a needle EMG is unlikely to be helpful.  
32       • Don't do a four-limb needle EMG/nerve conduction study (NCS) testing for neck  
33       and back pain after trauma.  
34       • Don't do nerve conduction studies without also doing a needle EMG for testing for  
35       radiculopathy, a pinched nerve in the neck or back.

36  
37       Sensitivity and specificity reports for electrodiagnostic testing methods (in general) vary.  
38       A clearly established measure of comparison is lacking in the medical literature, making  
39       comparisons across studies difficult. Some studies have compared results with clinical  
40       examination findings, imaging studies such as magnetic resonance imaging, computed  
41       tomography, myelography, or the observation of nerve root compression during surgery.  
42       Interobserver differences, the variety of tests employed, the presence of symptoms that

1 may influence patient outcomes (e.g., pain), the presence of abnormal imaging studies in  
 2 asymptomatic patients, and the subjectivity of the surgeon’s interpretations may all lead to  
 3 variances in sensitivity and specificity results. Despite these variances however,  
 4 electrodiagnostic testing is commonly used to assist in diagnosing disorders involving the  
 5 nerves, muscles, and neuromuscular junction. Sensitivity and specificity data for  
 6 automated/portable devices, used instead of or as an adjunct to standard nerve conduction  
 7 testing, is insufficient to draw conclusions regarding predictive value.

## 9 ***DOCUMENTATION GUIDELINES***

### 10 **Documentation Required Justifying Electrodiagnostic Testing**

- 11 • Reason for the study, clinical history and examination findings are required
- 12 • Numerical values are required – latency, amplitude and nerve conduction
- 13 • Type of needle – monopolar or concentric
- 14 • When documentation is required submit hard copy of waveforms and complete  
 15 written report, including test interpretation
- 16 • Name, signature, professional designation of all individuals performing,  
 17 interpreting or supervising the test must be included

### 19 **Inadequate Documentation**

- 20 • Narrative reports alluding to ‘normal’ or ‘abnormal’ results without numerical data
- 21 • Description of F-wave without reference to corresponding motor conduction data
- 22 • Pattern-setting unilateral H-reflex measurements
- 23 • Absence of clinical history, preferably written by the referral source, indicating the  
 24 need for the test
- 25 • Absence of documentation to support repeat testing on the same beneficiary or  
 26 testing every beneficiary referred for pain

28 Nerve conduction studies must provide a number of response parameters in a real-time  
 29 fashion to facilitate provider interpretation. Those parameters include amplitude, latency,  
 30 configuration and conduction velocity, temperature of limb. Diagnostic studies that do not  
 31 provide this information or those that provide delayed interpretation as substitutes for nerve  
 32 conduction studies are not accepted. Raw measurement data obtained and transmitted  
 33 trans-telephonically or over the Internet, therefore, does not qualify for the payment of the  
 34 electrodiagnostic service codes included in this policy.

36 Claims for nerve conduction testing accomplished with discriminatory devices that use  
 37 fixed anatomic templates and computer-generated reports used as an adjunct to physical  
 38 examination routinely on all patients are not accepted.

40 The AANEM provides specific recommendations for reporting needle EMG and NCV  
 41 results. According to the AANEM, the recommendation for documentation of nerve

1 conduction and EMG testing should include (but are not limited to) a description of the  
 2 patient’s clinical problem (demographics, reason for referral), the electrodiagnostic tests  
 3 performed (techniques, distances, lab reference values, and temperature monitoring), all  
 4 relevant data derived from these tests (nerves/muscles tested, numerical values for latencies  
 5 and action potential), and the diagnostic interpretation of the data, including limitations.  
 6 Complete NCV test measurements should also include amplitude measurements, normal  
 7 reference values and criteria for abnormalities. The recommendations also include  
 8 confirmation that limb temperature was monitored continuously during the NCS and  
 9 repetitive stimulation and that (a) the hand temperature was maintained between 32°C and  
 10 36°C and (b) the foot temperature was maintained between 30°C and 36°C. NCS  
 11 abnormalities such as prolonged distal sensory or motor latencies could otherwise be due  
 12 to coolness of the limb. For repetitive stimulation, if the limb is not warmed, the results  
 13 may be assessed inaccurately as normal (AANEM, 2019).

## 14 ***EVIDENCE REVIEW***

### 15 **Automated Nerve Conduction Testing**

16 Evidence evaluating the diagnostic utility of the Brevio and Virtual Medical Systems VT  
 17 3000 nerve conduction monitor systems (Automated Nerve Conduction Testing) is lacking.  
 18 Evidence evaluating the diagnostic utility of the NC-stat System consists mainly of case  
 19 series, case control studies and retrospective reviews. Some of these studies compare results  
 20 obtained using automated devices with results obtained from standard diagnostic testing  
 21 (NCV testing and EMG), other studies did not have a comparison to conventional testing.  
 22 Most of the published clinical studies have evaluated use of the NC-stat device for  
 23 assessment of median and ulnar nerves (Dale et al., 2015; Megerian et al., 2007; Kong et  
 24 al., 2006; Vinik et al., 2004); other published studies evaluated use of the device for  
 25 disorders such as lumbosacral radiculopathies (Fisher et al., 2008) and sensorimotor  
 26 polyneuropathy in diabetic patients (Perkins et al., 2008). In some of these studies a strong  
 27 correlation has been demonstrated when comparing NC-stat with reference standards  
 28 (Perkins et al., 2006; Kong et al., 2006). The diagnostic accuracy for other conditions, such  
 29 as those involving the lower extremities, has not been sufficiently demonstrated in the  
 30 literature. Data regarding diagnostic performance, sensitivity, and specificity of the  
 31 automated NCV testing devices compared to standard testing is inconsistent and does not  
 32 lead to strong conclusions; the studies are not well-designed, involve small populations and  
 33 the results cannot be generalized. In some studies authors have reported high sensitivity  
 34 and specificity when examining NC-stat accuracy for carpal tunnel syndrome compared to  
 35 controls (Dale et al., 2015; Leffler et al., 2000; Rotman et al., 2004), other authors however  
 36 have reported NC-stat is no more sensitive or specific than a traditionally performed distal  
 37 motor latency for the diagnosis of carpal tunnel syndrome (Katz, 2006). In 2008,  
 38 Armstrong and colleagues published the outcomes of a cohort study comparing the results  
 39 obtained with the NC-stat device to traditional nerve conduction studies for carpal tunnel  
 40 screening ( $n=33$ ). All correlations were significant. The authors reported sensitivity, with  
 41 respect to the traditional results, ranged from 93.8% to 100% and specificity ranged from  
 42

1 84.6% to 94.1%. Nonetheless, the authors did not address limitations such as lack of needle  
 2 EMG testing and did not evaluate the clinical relevance to the results (Armstrong et al.,  
 3 2008). In a longitudinal study ( $n=134$ ), Dale and colleagues (2015) compared automated  
 4 nerve conduction using the NC Stat device to traditional electrodiagnostic studies for 62  
 5 subjects, who had prior evaluation for carpal tunnel syndrome in the parent study ( $n=780$ ).  
 6 The authors reported that NC Stat results agreed with traditional electrodiagnostic studies  
 7 for detecting median nerve conduction abnormalities within a general population of  
 8 workers. Ulnar nerve testing results were not as favorable however median nerve testing  
 9 results had high sensitivity and specificity (86-100%) for median motor and sensory  
 10 latency. The study is limited by small sample population of industrial workers; results  
 11 cannot be generalized to the standard population. A technology assessment conducted by  
 12 the Washington State Department of Labor and Industries (2006) concluded that the  
 13 scientific evidence does not show NC-stat to be equivalent to conventional methods for  
 14 nerve conduction testing. Authors generally agree that further studies are needed to  
 15 determine the role automated testing has as a component of clinical care. Furthermore,  
 16 some concerns remain among specialists regarding lack of standard EMG testing and  
 17 incomplete assessment when using automated NCV testing devices. The AANEM  
 18 recommends electrodiagnostic studies be performed by properly trained physicians and  
 19 that interpretation of nerve conduction study data alone, absent face-to-face patient  
 20 interaction and control over the process, provides substandard care (AANEM, 2006). The  
 21 AANEM (2010) does not support the following:

- 22 • Electrodiagnostic testing with automated, noninvasive nerve conduction testing  
 23 devices
- 24 • Screening testing, monitoring disease intensity, or monitoring treatment efficacy  
 25 for polyneuropathy of diabetes or polyneuropathy of end stage renal disease  
 26 (ESRD)

27  
 28 Schmidt and colleagues (2011) reported on the use of an automated hand-held nerve  
 29 conduction device compared to NCS or needle electrode examination (standard  
 30 electrodiagnostic tests) in the evaluation of individuals with unilateral leg symptoms. A  
 31 total of 50 participants with complaints of unilateral leg pain, numbness or weakness were  
 32 included in the study and underwent history with physical exam and standard  
 33 electrodiagnostic testing. The participants were then tested using an automated hand-held  
 34 nerve conduction device. A total of 22 participants had findings consistent with  
 35 radiculopathy on standard electrodiagnostic test and 28 participants had a normal  
 36 electrodiagnostic exam or evidence of another distinct neuromuscular diagnosis. During  
 37 initial data analysis, a significant discrepancy was revealed between the results of standard  
 38 electrodiagnostic tests and the automated test. For this reason, another 25 participants were  
 39 recruited to serve as the control group. The control group participants had upper limb  
 40 symptoms such as cervical radiculopathy, carpal tunnel syndrome or ulnar neuropathy. Of  
 41 the 50 participants initially recruited, 28 were found to have normal standard  
 42 electrodiagnostic tests. The automated tests corroborated the findings in 4 cases only. In

1 the control group, all standard electrodiagnostic tests were normal, but the automated  
2 testing showed 18 of 25 participants had findings consistent with radiculopathy or  
3 polyneuropathy. Automated and standard testing correlated in 14 of 75 participants studied  
4 (11 of whom had normal exams with both testing methods). While this study has a small  
5 number of participants, the authors stated that "it is unlikely that larger study numbers  
6 would have increased specificity to acceptable levels of a clinically useful test, given the  
7 95% confidence levels for the current data."  
8

9 In a position statement on the Proper Performance and Interpretation of Electrodiagnostic  
10 Studies and the Recommended Use of Electrodiagnostic Medicine from the American  
11 Association of Neuromuscular and Electrodiagnostic Medicine (AANEM, 2006, 2014,  
12 2020), although no specific reference to or recommendation for automated nerve  
13 conduction testing devices is made, it is noted that "Because needle EMG studies offer  
14 information needed for an accurate diagnosis, except in unique situations, it is the  
15 AANEM's position that NCSs and needle EMGs should be performed together in the same  
16 setting." The document also notes that using only NCS may provide incomplete diagnostic  
17 information which could lead to inadequate or inappropriate treatment. And: Individuals  
18 without a medical education in neuromuscular disorders and without special training in  
19 EDX procedures typically are not qualified to interpret the waveforms generated by NCSs  
20 and needle EMGs or to correlate the findings with other clinical information to reach a  
21 diagnosis. It is also the recommendation of the American Association of Neuromuscular  
22 and Electrodiagnostic Medicine (AANEM) that electrodiagnostic testing/consultations are  
23 conducted by physicians who have a comprehensive knowledge of neurological and  
24 neuromusculoskeletal diseases, and in the application of neurophysiologic techniques for  
25 evaluation of those disorders.  
26

27 Although portable, automated, noninvasive testing of nerve conduction has been suggested  
28 as an easier method for providers to obtain rapid results, the AANEM recommended that  
29 EDX studies of EMG and NCS be performed "by physicians with medical education in  
30 neuromuscular disorders and special training in EDX testing" (AANEM, 2020). Currently,  
31 there is insufficient evidence in peer-reviewed published literature to demonstrate that  
32 automated nerve conduction testing devices provide better measures in the diagnosis of  
33 peripheral nerve disease. In addition, it remains unclear how testing with portable devices  
34 improves clinical outcomes for populations such as diabetics compared to clinical detection  
35 through neurological examination.  
36

37 Since the clearance of the NC-stat, several other devices have also received FDA clearance  
38 listing the NC-stat as the predicate device. However, to date there has been very limited  
39 published evidence to demonstrate the safety and efficacy of automated, noninvasive nerve  
40 conduction testing devices, as compared to conventional "gold standard" electrodiagnostic  
41 testing using EMG and NCS. Most of the published clinical studies have evaluated use of

1 an automated device for assessment of the median and ulnar nerves only (Katz, 2006;  
2 Kong, 2006).

### 3 **Other Electrodiagnostic Testing**

4 Evidence in the peer reviewed scientific literature including textbook and professional  
5 society opinion supports clinical utility for electrodiagnostic testing, including  
6 neuromuscular junction testing, when used to assist in diagnosing disorders involving the  
7 nerves, muscles and neuromuscular junction. The AANEM has published guidance for the  
8 performance of nerve conduction studies and EMG. According to the AANEM a typical  
9 nerve conduction examination includes development of a differential diagnosis based upon  
10 appropriate history and physical exam, the NCV study (recording and studying of electrical  
11 responses from peripheral nerves or muscles) and the completion of indicated needle EMG  
12 studies to evaluate the differential diagnosis and to complement the nerve conduction  
13 study. In addition, the AANEM supports that when performing nerve conduction studies,  
14 the waveform must be reviewed on site and in real time, with reports prepared onsite by  
15 the examiner, consistent with current procedural terminology descriptions (AANEM,  
16 2014). The AANEM defines the use of the term onsite as that where the history and  
17 physical, performance of NCV and EMG, analysis of electrodiagnostic data and  
18 determination of diagnosis occur in the same location, typically an electrodiagnostic  
19 laboratory. Similarly, real time is defined as that which allows for information from the  
20 physical and history to be integrated with the performance of testing, allowing for the  
21 testing of both NCV and EMG to be tailored/modified to the individual circumstance as  
22 needed before leaving the lab.  
23

24  
25 The use of nerve conduction studies including F-wave and H-reflex tests for the diagnosis  
26 of early stage polyneuropathies and proximal nerve lesions is confirmed in several reviews  
27 and studies (Choi and Maria, 2021; Maccabee et al., 2011; Kostera-Pruszczyk et al., 2004;  
28 Trujillo-Hernandez et al., 2005; Bal et al., 2006; Kocer et al., 2005; Mesrati and  
29 Vecchierini, 2004). The published scientific literature demonstrates somatosensory evoked  
30 potential (SEP) studies are useful when used to aid in the diagnosis of various  
31 neuromuscular disorders and have varying degrees of sensitivity and specificity.  
32

33 Nerve conduction studies are indicated for the following conditions: peripheral nerve  
34 entrapment (Omejec, 2014; Park, 2014; Calfee, 2012; Kwon, 2008; Vij et al., 2021);  
35 generalized neuropathies (Choi and Maria, 2021; Holiner, 2013; Derr, 2009; Dyck, 2010;  
36 De Sousa, 2009); polyneuropathies (Choi and Maria, 2021; de Souza, 2015; Emeryk-  
37 Szajewska, 1998; Torvin Moller, 2009); plexopathy (Mullins, 2007); neuromuscular  
38 junction disorders (Meriggioli, 2005); myopathies including polymyositis,  
39 dermatomyositis, and congenital myopathies (Wang, 2010); motor neuron disease  
40 (Hammad, 2007); spine disorders and radiculopathy (Pawar, 2013; Alrawi, 2007; Haig,  
41 2006); and guidance for botulinum toxin injection for spasmodic dysphonia or segmental  
42 dystonia, when it is difficult to isolate affected muscles (Molloy, 2002).

1 Karami-Mohajeri et al. (2014) presented a systematic review of the recent literature on the  
2 scientific support of EMG and NCV in diagnosing the exposure and toxicity of  
3 organophosphorus pesticides (OP). Specifically, this review focused on changes in EMG,  
4 NCV, occurrence of intermediate syndrome (IMS), and OP-induced delayed  
5 polyneuropathy (OPIDN) in human. All relevant bibliographic databases were searched  
6 for human studies using the key words "OP poisoning", "electromyography", "nerve  
7 conduction study," and "muscles disorders". Intermediate syndrome usually occurs after  
8 an acute cholinergic crisis, while OPIDN occurs after both acute and chronic exposures.  
9 Collection of these studies supported that IMS is a neuromuscular junction disorder and  
10 can be recorded upon the onset of respiratory failure. Due to heterogeneity of reports on  
11 outcomes of interest such as motor NCV and EMG amplitude in acute cases and inability  
12 to achieve precise estimation of effect in chronic cases meta-analysis was not helpful to  
13 this review. The OPIDN after both acute and low-level prolonged exposures develops  
14 peripheral neuropathy without preceding cholinergic toxicity and the progress of changes  
15 in EMG and NCV is parallel with the development of IMS and OPIDN. Persistent  
16 inhibition of acetylcholinesterase (AChE) is responsible for muscle weakness, but this is  
17 not the only factor involved in the incidence of this weakness in IMS or OPIDN suggestive  
18 of AChE assay not useful as an index of nerve and muscle impairment. The authors  
19 concluded that although several mechanisms for induction of this neurodegenerative  
20 disorder have been proposed, among them oxidative stress and resulting apoptosis can be  
21 emphasized. Nevertheless, they stated that there is little synchronized evidence on  
22 subclinical electrophysiological findings that limit these investigators to reach a strong  
23 conclusion on the diagnostic or prognostic use of EMG and NCV for acute and  
24 occupational exposures to OPs.

25  
26 Asad et al. (2009) compared the nerve conduction studies in clinically undetectable and  
27 detectable sensorimotor polyneuropathy in type 2 diabetics. Diagnosed diabetics ( $n = 60$ )  
28 were divided in two groups. Group 1 ( $n_1 = 30$ ) with clinically undetectable and group 2  
29 ( $n_2 = 30$ ) with clinically detectable Diabetic Polyneuropathy. Detection of the  
30 sensorimotor neuropathy was done according to Diabetic Neuropathy Symptom Score and  
31 Diabetic Neuropathy Examination scores. The simplified nerve conduction studies  
32 protocol was followed in recording amplitudes, velocities and latencies of minimum two  
33 (Sural, Peroneal) and maximum six i.e., three sensory (Sural, Ulnar, Median) and three  
34 motor (Peroneal, Ulnar, Tibial) nerves. The comparisons were done between different  
35 parameters of nerve conduction studies with the neurological scores in undetectable and  
36 detectable groups using Pearson's chi square test. The amplitudes, velocities, latencies,  
37 outcome and grading of neuropathy in nerve conduction studies when compared with  
38 neurological detection scores showed a significant relation in each group regarding  
39 evaluation ( $p = 0.005$ ,  $p = 0.004$ ,  $p = 0.05$ ,  $p = 0.00001$ ,  $p = 0.003$  respectively). Diabetic  
40 Neuropathy Symptom Score and Diabetic Neuropathy Examination Score together can  
41 help in prompt evaluation of the diabetic sensorimotor polyneuropathy though nerve  
42 conduction study is more powerful test and can help in diagnosing subclinical cases.

## 1 **Surface Electromyography (SEMG)**

2 There is a wide variety of Surface Electromyography (SEMG) hardware and software that  
3 is used depending upon the specific clinical purpose intended. However, all SEMG  
4 hardware and software have in common the following:

- 5 • Electrical signals are measured from skeletal muscles.
- 6 • Sensing electrodes are placed on the skin overlying the muscle of interest.
- 7 • The electrical activity is measured when the muscle is active.
- 8 • SEMG records a narrow frequency of electrical activity (20-500 Hz).
- 9 • SEMG findings are based on computer analysis of either the frequency spectrum  
10 (spectral analysis), amplitude of signal, or root mean square of electrical action  
11 potentials.

## 12 **The Evaluation of Specific Neuromuscular Pathologies**

13 The literature on the subject of SEMG use for neuromuscular disorders indicates that it is  
14 inferior in all parameters (sensitivity, specificity, spatial resolution, signal to noise ratio) to  
15 the invasive procedures such as needle electromyography (NEMG) or fine-wire  
16 electromyography (FWEMG) and thus cannot be used as a substitute for those procedures.  
17 Both systematic reviews of this subject explicitly reject SEMG for the diagnosis of  
18 neuromuscular disease.  
19

20  
21 The gold standard for this type of evaluation is either NEMG or FWEMG. Because these  
22 procedures are both invasive and painful, there is an obvious desire to find equally useful,  
23 but less onerous diagnostic tests. There are, however, several inherent limitations to the use  
24 of SEMG for the analysis of neuromuscular pathology. SEMG records input from a much  
25 wider spatial field than do either of the invasive procedures. Muscles adjacent to those of  
26 interest can produce signals that appear to originate from the target muscles (which are  
27 located immediately beneath the sensing electrodes). Thus, the specificity of SEMG  
28 findings is always in doubt. SEMG is also very susceptible to movement artifact. Even  
29 with the most careful procedural safeguards, small (and even imperceptible) body  
30 movements may produce spurious signals. There is a much poorer signal to noise ratio with  
31 SEMG. This is particularly a problem when target muscles are located more than 10 mm  
32 below the skin surface. Finally, the electrical activity that is recorded by SEMG is only of  
33 skeletal muscle origins. It is not possible to capture any electrical activity along motor  
34 neuron axons, as it is with NEMG or FWEMG.  
35

## 36 **The Evaluation of Movement and Gait Disturbances**

37 There are a variety of experimental applications such as studies of human movement, the  
38 study of nerve conduction velocities after electrical stimulation of peripheral nerves, etc.,  
39 in which SEMG is considered standard. Because of its relative ease of use and non-invasive  
40 nature, SEMG is considered superior to NEMG and FWEMG for many of these  
41 applications. There are also thought to be advantages in using SEMG to evaluate/study  
42 movement disorders of CNS origins such as tremor, dystonia, dyskinesia, and myoclonus.



1 While it is thought that SEMG can accurately measure these disorders, it is less clear what  
2 the clinical utility of these measurements might be. This is the only application for which  
3 the American Medical Association (AMA) Current Procedural Terminology (CPT) coding  
4 committee has developed a procedure code.

### 6 **The Evaluation of Functional Back Pain**

7 There are a number of studies that have investigated the possibility that SEMG may  
8 differentiate between those with and those without back pain by evaluating muscle fatigue  
9 through “spectral shift”. However, the findings are inconsistent and contradictory, the  
10 relationship between muscle fatigue and back pain is not established, and there may be  
11 unrelated factors affecting spectral shift.

12  
13 The clinical context in which chiropractors are most likely to use SEMG is for the  
14 evaluation of functional low back pain and neck pain. There are two proposed mechanisms  
15 by which SEMG is thought to relate to back pain. First is the presumed relationship  
16 between muscle fatigue and back pain. The theory posits that excessive muscle fatigue, due  
17 to deconditioning, may result in back pain. Further, it has been shown that when muscles  
18 fatigue they produce a different set of electrical frequencies as measured by SEMG. This  
19 phenomenon has been dubbed the “spectral shift.” Thus, it has been hypothesized that by  
20 using dynamic SEMG (recording muscle activity while exercising) it should be possible to  
21 differentiate those with back pain from those without back pain. There are a number of  
22 studies that have investigated this possibility, and some have had success in doing so.  
23 However, this success is tempered by several caveats. First, these findings are inconsistent  
24 and somewhat contradictory. Second, the exact nature of the relationship between muscle  
25 fatigue and back pain is uncertain. In fact, the direction of the relationship is uncertain—  
26 does muscle fatigue cause back pain or does back pain cause muscle fatigue? Third, it is  
27 unclear what other factors might cause a spectral shift making the specificity of such  
28 findings doubtful.

29  
30 There is another mechanism by which it is proposed that SEMG can assist in the evaluation  
31 of back pain: the identification of hypertonic muscles. It is this mechanism that the leading  
32 chiropractic proponents of SEMG suggest is the most relevant to patient management. In  
33 effect, it is proposed that SEMG is a more objective and accurate tool than palpation in  
34 locating hypertonic muscles and thereby the identification of vertebral subluxations. The  
35 literature relative to this mechanism is even more limited and of much poorer quality than  
36 is the literature on muscle fatigue and SEMG. It is also speculated that the finding of SEMG  
37 asymmetry is an indication of spinal dysfunction. There is no literature that finds a  
38 relationship between back pain and such asymmetry and at least one study that casts doubt  
39 on this hypothesis. SEMG is not reliable for assessing spinal dysfunction or subluxation.

40  
41 An analysis by Triano et al. (2013) examined the techniques and procedures used by  
42 chiropractors to identify the appropriate site for the application of spinal manipulation.

1 Consistent with previous reviews they found limited support for reliability of SEMG to  
 2 identify cohorts of patients with abnormal neuromuscular control. However, the review  
 3 concluded that there was no support for the use of SEMG to localize treatment to a specific  
 4 site. Another area of research for SEMG is its use as a prognostic tool. Studies have looked  
 5 at flexion and extension movements to determine the prognosis of the patient relative to  
 6 their low back pain recovery. Hu et al. (2014) evaluated the prognostic value of quantitative  
 7 SEMG topographic analysis and attempted to verify the accuracy of the performance of  
 8 proposed time-varying topographic parameters for identifying the patients who have better  
 9 response toward the rehabilitation program. Thirty-eight patients with chronic nonspecific  
 10 LBP and 43 healthy subjects were included in the study. These patients suffered from  
 11 chronic nonspecific LBP without the history of back surgery and any medical conditions  
 12 causing acute exacerbation of LBP during the clinical test were enlisted to perform the  
 13 clinical test during the 12-week physiotherapy (PT) treatment. Low back pain patients were  
 14 classified into two groups: "responding" and "nonresponding" based on the clinical  
 15 assessment. The responding group referred to the LBP patients who began to recover after  
 16 the PT treatment, whereas the nonresponding group referred to some LBP patients who did  
 17 not recover or got worse after the treatment. The quantitative time-varying analysis of  
 18 SEMG topography showed significant difference between the healthy and LBP groups.  
 19 The discrepancies in quantitative dynamic SEMG topography of LBP group from normal  
 20 group, were able to identify those LBP subjects who would respond to a conservative  
 21 rehabilitation program focused on functional restoration of lumbar muscle. More research  
 22 is needed to confirm results and evaluate its utility clinically.

23  
 24 In assessing the appropriateness of SEMG for functional back pain, there are three levels  
 25 of analysis to consider that remain pertinent:

- 26 1. **Technical performance of the instrument.** To what extent does the instrument  
 27 accurately measure what it purports to measure (e.g., muscle fatigue, muscle  
 28 spasm)? The above discussion regarding neuromuscular disorders identifies several  
 29 inherent limitations in the technical performance of SEMG. All of those limitations  
 30 (with the exception of the inability to measure axonal signals) are relevant to this  
 31 issue as well. The lack of specificity, poor signal to noise ratio, and the problem of  
 32 movement artifacts will all limit the accuracy and validity of SEMG for the  
 33 evaluation of functional back pain.
- 34  
 35 2. **Whether and how the instrument findings can be used in patient management.**  
 36 The use of SEMG as a "subluxation detector" that can help identify specific levels  
 37 of spinal dysfunction has not been substantiated and is entirely speculative.

38  
 39 If it has been determined that it is possible to identify hypo- or hypertonic muscles  
 40 through the use of SEMG (keeping in mind the inherent technical limitations  
 41 affecting specificity, accuracy, and validity), the question becomes how this  
 42 information will be used in the management of the patient. To date, the only clinical

1 correlation that has been established is that there *may* be differences between  
 2 subjects with back pain and control subjects in their muscle fatigability as measured  
 3 by SEMG. In other words, it may be possible to differentiate those with and without  
 4 back pain using SEMG. But as one of the systematic reviews points out, the gold  
 5 standard for the presence or absence of back pain is the clinical history, and it is far  
 6 easier and more reliable to simply ask the person whether he or she has back pain.  
 7 While potentially, it might be possible to use SEMG to identify malingerers, the  
 8 procedure is currently far too unreliable to permit any such determination to be  
 9 predicated on SEMG findings. In addition, several established malingering tests are  
 10 available as taught within standard orthopedic examination courses in chiropractic,  
 11 osteopathic, and medical schools.

- 12  
 13 **3. Whether the use of an instrument results in better clinical outcomes.** There is  
 14 no evidence (and very little theory) to indicate how specific SEMG findings should  
 15 be used to manage individuals with back pain in order to produce better clinical  
 16 outcomes.

17  
 18 Ultimately what matters is whether or not the use of SEMG results in better clinical  
 19 outcomes than does the management of back pain without the use of SEMG  
 20 information. There have been no clinical trials that have addressed this question. In  
 21 fact, there are no clinical trials of back pain that have used SEMG in any aspect of  
 22 the diagnosis of subjects, in measuring outcomes of treatment, or otherwise  
 23 evaluating the effectiveness of the therapeutic intervention (e.g., chiropractic  
 24 treatment).

25  
 26 ***PRACTITIONER SCOPE AND TRAINING***

27 Practitioners should practice only in the areas in which they are competent based on their  
 28 education, training, and experience. Levels of education, experience, and proficiency may  
 29 vary among individual practitioners. It is ethically and legally incumbent on a practitioner  
 30 to determine where they have the knowledge and skills necessary to perform such services  
 31 and whether the services are within their scope of practice.

32  
 33 It is best practice for the practitioner to appropriately render services to a member only if  
 34 they are trained, equally skilled, and adequately competent to deliver a service compared  
 35 to others trained to perform the same procedure. If the service would be most competently  
 36 delivered by another health care practitioner who has more skill and training, it would be  
 37 best practice to refer the member to the more expert practitioner.

38  
 39 Best practice can be defined as a clinical, scientific, or professional technique, method, or  
 40 process that is typically evidence-based and consensus driven and is recognized by a  
 41 majority of professionals in a particular field as more effective at delivering a particular

1 outcome than any other practice (Joint Commission International Accreditation Standards  
2 for Hospitals, 2020).

3  
4 Depending on the practitioner’s scope of practice, training, and experience, a member’s  
5 condition and/or symptoms during examination or the course of treatment may indicate the  
6 need for referral to another practitioner or even emergency care. In such cases it is prudent  
7 for the practitioner to refer the member for appropriate co-management (e.g., to their  
8 primary care physician) or if immediate emergency care is warranted, to contact 911 as  
9 appropriate. See the *Managing Medical Emergencies (CPG 159 – S)* clinical practice  
10 guideline for information.

### 11 **References**

- 12 AANEM. AANEM's top five choosing wisely recommendations. *Muscle Nerve*.  
13 2015;51(4):617-619. doi:10.1002/mus.24628  
14  
15  
16 Ahern DK, Follick MJ, Council JR, Laser-Wolston N. Reliability of lumbar paravertebral  
17 EMG assessment in chronic low back pain. *Arch Phys Med Rehabil*. 1986;67(10):762-  
18 765. doi:10.1016/0003-9993(86)90014-6  
19  
20 Ahern DK, Follick MJ, Council JR, Laser-Wolston N, Litchman H. Comparison of lumbar  
21 paravertebral EMG patterns in chronic low back pain patients and non-patient  
22 controls. *Pain*. 1988;34(2):153-160. doi:10.1016/0304-3959(88)90160-1  
23  
24 Alemo S, Sayadipour A. Role of intraoperative neurophysiologic monitoring in  
25 lumbosacral spine fusion and instrumentation: a retrospective study. *World Neurosurg*.  
26 2010;73(1):72-e7. doi:10.1016/j.surneu.2009.04.024  
27  
28 Alexiev AR. Some differences of the electromyographic erector spinae activity between  
29 normal subjects and low back pain patients during the generation of isometric trunk  
30 torque. *Electromyogr Clin Neurophysiol*. 1994;34(8):495-499  
31  
32 Alrawi MF, Khalil NM, Mitchell P, Hughes SP. The value of neurophysiological and  
33 imaging studies in predicting outcome in the surgical treatment of cervical  
34 radiculopathy. *Eur Spine J*. 2007;16(4):495-500. doi:10.1007/s00586-006-0189-6  
35  
36 Al-Shehlee A, Shapiro BE, Preston DC. Iatrogenic complications and risks of nerve  
37 conduction studies and needle electromyography. *Muscle Nerve*. 2003;27(5):517-526.  
38 doi:10.1002/mus.10315  
39  
40 Ambroz C, Scott A, Ambroz A, Talbott EO. Chronic low back pain assessment using  
41 surface electromyography. *J Occup Environ Med*. 2000;42(6):660-669.  
42 doi:10.1097/00043764-200006000-00018

1 American Academy of Neurology (AAN). Position statement. Mobile electrodiagnostic  
2 laboratories provide substandard patient care. 2015. Updated and reapproved August  
3 2020. Retrieved on July 4, 2024 from [https://www.aanem.org/clinical-practice-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/mobile-electrodiagnostic-laboratories-provide-substandard-patient-care)  
4 [resources/position-statements/position-statement/mobile-electrodiagnostic-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/mobile-electrodiagnostic-laboratories-provide-substandard-patient-care)  
5 [laboratories-provide-substandard-patient-care](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/mobile-electrodiagnostic-laboratories-provide-substandard-patient-care)  
6

7 American Academy of Neurology (AAN). Principles of coding for intraoperative  
8 neurophysiologic monitoring (IOM) and testing model medical policy. 2012. Retrieved  
9 on July 4, 2024 from [https://www.aan.com/siteassets/home-page/tools-and-](https://www.aan.com/siteassets/home-page/tools-and-resources/practicing-neurologist--administrators/billing-and-coding/model-coverage-policies/16iommodelpolicy_tr.pdf)  
10 [resources/practicing-neurologist--administrators/billing-and-coding/model-coverage-](https://www.aan.com/siteassets/home-page/tools-and-resources/practicing-neurologist--administrators/billing-and-coding/model-coverage-policies/16iommodelpolicy_tr.pdf)  
11 [policies/16iommodelpolicy\\_tr.pdf](https://www.aan.com/siteassets/home-page/tools-and-resources/practicing-neurologist--administrators/billing-and-coding/model-coverage-policies/16iommodelpolicy_tr.pdf)  
12

13 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).  
14 Definition of real time onsite. Position Statement. July 2014. Retrieved on July 4, 2024  
15 from [https://www.aanem.org/clinical-practice-resources/position-statements/position-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/definition-of-real-time-onsite)  
16 [statement/definition-of-real-time-onsite](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/definition-of-real-time-onsite)  
17

18 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).  
19 Model Policy for Nerve Conduction Studies and Needle Electromyography 2016.  
20 Retrieved on July 4, 2024 from [https://www.aanem.org/clinical-practice-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/model-policy-for-nerve-conduction-studies-and-needle-electromyography)  
21 [resources/position-statements/position-statement/model-policy-for-nerve-conduction-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/model-policy-for-nerve-conduction-studies-and-needle-electromyography)  
22 [studies-and-needle-electromyography](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/model-policy-for-nerve-conduction-studies-and-needle-electromyography)  
23

24 American Association of Neuromuscular & Electrodiagnostic Medicine. Needle EMG in  
25 certain uncommon clinical contexts. *Muscle Nerve*. 2005;31(3):398-399.  
26 doi:10.1002/mus.20238  
27

28 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).  
29 Position Statement. Reporting the results of needle EMG and nerve conduction studies:  
30 and educational report. May 2014. Updated and reapproved July 2018. Retrieved on  
31 July 4, 2024 from: [https://www.aanem.org/clinical-practice-resources/position-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/reporting-the-results-of-nerve-conduction-studies-and-needle-emg)  
32 [statements/position-statement/reporting-the-results-of-nerve-conduction-studies-and-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/reporting-the-results-of-nerve-conduction-studies-and-needle-emg)  
33 [needle-emg](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/reporting-the-results-of-nerve-conduction-studies-and-needle-emg)  
34

35 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).  
36 Position Statement. Technologist Performance Of Nerve Conduction Studies And  
37 Somatosensory Evoked Potentials Under Direct Edx Physician Supervision. Approved  
38 by the American Association of Electrodiagnostic Medicine May 1999b. Modified and  
39 approved August 2020. Retrieved on July 4, 2024 from  
40 [https://www.aanem.org/docs/default-](https://www.aanem.org/docs/default-source/documents/aanem/advocacy/technologists-conducting-ncs_sep_2020.pdf?sfvrsn=132d3dd3_3)  
41 [source/documents/aanem/advocacy/technologists-conducting-](https://www.aanem.org/docs/default-source/documents/aanem/advocacy/technologists-conducting-ncs_sep_2020.pdf?sfvrsn=132d3dd3_3)  
42 [ncs\\_sep\\_2020.pdf?sfvrsn=132d3dd3\\_3](https://www.aanem.org/docs/default-source/documents/aanem/advocacy/technologists-conducting-ncs_sep_2020.pdf?sfvrsn=132d3dd3_3)

- 1 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).  
 2 Practice parameter for Repetitive Nerve Stimulation & Single Fiber EMG Evaluation  
 3 of Adults w/Suspected Myasthenia Gravis. Reaffirmed October 2015. Retrieved on  
 4 July 4, 2024 from [https://www.aanem.org/clinical-practice-](https://www.aanem.org/clinical-practice-resources/guidelines/guideline/practice-parameter-for-rns-and-single-fiber-emg-eval-of-adults-with-suspected-mg)  
 5 [resources/guidelines/guideline/practice-parameter-for-rns-and-single-fiber-emg-eval-](https://www.aanem.org/clinical-practice-resources/guidelines/guideline/practice-parameter-for-rns-and-single-fiber-emg-eval-of-adults-with-suspected-mg)  
 6 [of-adults-with-suspected-mg](https://www.aanem.org/clinical-practice-resources/guidelines/guideline/practice-parameter-for-rns-and-single-fiber-emg-eval-of-adults-with-suspected-mg)  
 7
- 8 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).  
 9 Proper performance and interpretation of electrodiagnostic studies. Muscle Nerve.  
 10 2006 Mar;33(3):436-9. Reviewed and updated Jan 2020. Retrieved on July 4, 2024  
 11 from [https://www.aanem.org/clinical-practice-resources/position-statements/position-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/proper-performance-and-interpretation-of-electrodiagnostic-studies)  
 12 [statement/proper-performance-and-interpretation-of-electrodiagnostic-studies](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/proper-performance-and-interpretation-of-electrodiagnostic-studies)  
 13
- 14 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).  
 15 (2020). Risks in electrodiagnostic medicine. Retrieved on July 4, 2024 from  
 16 [https://www.aanem.org/clinical-practice-resources/position-statements/position-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/risks-in-electrodiagnostic-medicine)  
 17 [statement/risks-in-electrodiagnostic-medicine](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/risks-in-electrodiagnostic-medicine)  
 18
- 19 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).  
 20 Somatosensory evoked potentials. Clinical uses. Chapter 5. Muscle Nerve 22:  
 21 Supplement 8: S111-S118, 1999a. Retrieved on July 4, 2024 from  
 22 [https://www.aanem.org/clinical-practice-](https://www.aanem.org/clinical-practice-resources/guidelines/guideline/somatosensory-evoked-potentials-clinical-uses)  
 23 [resources/guidelines/guideline/somatosensory-evoked-potentials-clinical-uses](https://www.aanem.org/clinical-practice-resources/guidelines/guideline/somatosensory-evoked-potentials-clinical-uses)  
 24
- 25 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). Who  
 26 is qualified to practice electrodiagnostic medicine. Position statement. Updated and Re-  
 27 approved: May 2012; November 2017, April 2024, Retrieved on July 4, 2024 from  
 28 [https://www.aanem.org/clinical-practice-resources/position-statements/position-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/who-is-qualified-to-practice-electrodiagnostic-medicine)  
 29 [statement/who-is-qualified-to-practice-electrodiagnostic-medicine](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/who-is-qualified-to-practice-electrodiagnostic-medicine)  
 30
- 31 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).  
 32 Model Policy for Nerve Conduction Studies and Needle Electromyography. Updated  
 33 and reapproved Dec 2022. Retrieved on July 4, 2024 from  
 34 [https://www.aanem.org/clinical-practice-resources/position-statements/position-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/model-policy-for-nerve-conduction-studies-and-needle-electromyography)  
 35 [statement/model-policy-for-nerve-conduction-studies-and-needle-electromyography](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/model-policy-for-nerve-conduction-studies-and-needle-electromyography)  
 36
- 37 American Clinical Neurophysiology Society (ACNS). Guidelines for short latency  
 38 somatosensory evoked potentials. Feb 10, 2006. Retrieved on July 4, 2024 from  
 39 <https://www.acns.org/practice/guidelines>

- 1 American Medical Association. (current year) Current Procedural Terminology (CPT)  
2 Current year (rev. ed.), Chicago: AMA.  
3
- 4 American Society of Electroneurodiagnostic Technologists (ASET). National competency  
5 skill standards for performing Intraoperative neurophysiologic monitoring. Retrieved  
6 on July 4, 2024 from [https://www.aset.org/wp-](https://www.aset.org/wp-content/uploads/2022/01/IONM_National_Competency_Skill_Standards_Approved_2011.pdf)  
7 [content/uploads/2022/01/IONM\\_National\\_Competency\\_Skill\\_Standards\\_Approved\\_](https://www.aset.org/wp-content/uploads/2022/01/IONM_National_Competency_Skill_Standards_Approved_2011.pdf)  
8 [2011.pdf](https://www.aset.org/wp-content/uploads/2022/01/IONM_National_Competency_Skill_Standards_Approved_2011.pdf)  
9
- 10 American Society of Neurophysiological Monitoring (ASNM). Intraoperative monitoring  
11 using somatosensory evoked potentials. A position statement by the American Society  
12 of Neurophysiological Monitoring. *J Clin Monit Comput.* 2005 Jun;241-58 (18).  
13
- 14 American Speech-Language-Hearing Association. Neurophysiologic Intraoperative  
15 Monitoring. Position Statement. Copyright©2013 American Language-Speech-  
16 Hearing Association. Retrieved on July 4, 2024 from  
17 <http://www.asha.org/policy/PS1992-00036/>  
18
- 19 Aminoff MJ, Eisen A. Somatosensory Evoked Potentials. In: Aminoff's Electrodiagnosis  
20 in Clinical Neurology. Ch 26. Sixth Edition © 2012, Elsevier Inc.  
21
- 22 Aminoff MJ. Electrophysiologic testing for the diagnosis of peripheral nerve  
23 injuries. *Anesthesiology.* 2004;100(5):1298-1303. doi:10.1097/00000542-200405000-  
24 00034  
25
- 26 Armstrong TN, Dale AM, Al-Lozi MT, Franzblau A, Evanoff BA. Median and ulnar nerve  
27 conduction studies at the wrist: criterion validity of the NC-stat automated device. *J*  
28 *Occup Environ Med.* 2008;50(7):758-764. doi:10.1097/JOM.0b013e3181645425  
29
- 30 Asad A, Hameed MA, Khan UA, Butt MU, Ahmed N, Nadeem A. Comparison of nerve  
31 conduction studies with diabetic neuropathy symptom score and diabetic neuropathy  
32 examination score in type-2 diabetics for detection of sensorimotor polyneuropathy. *J*  
33 *Pak Med Assoc.* 2009;59(9):594-598  
34
- 35 Asbury AK. Approach to the patient with peripheral neuropathy. In: Harrison's Principles  
36 of Internal Medicine. Part 15: Neurologic disorders. Section 3: Nerve and muscle  
37 disorders. Chapter 363. Electrodiagnosis. Copyright 2004 by The McGraw-Hill  
38 Companies, Inc.  
39
- 40 Assessment: dermatomal somatosensory evoked potentials. Report of the American  
41 Academy of Neurology's Therapeutics and Technology Assessments  
42 Subcommittee. *Neurology.* 1997;49(4):1127-1130

- 1 Assessment: intraoperative neurophysiology. Report of the Therapeutics and Technology  
2 Assessment Subcommittee of the American Academy of Neurology. *Neurology*.  
3 1990;40(11):1644-1646  
4
- 5 Bal S, Celiker R, Palaoglu S, Cila A. F wave studies of neurogenic intermittent claudication  
6 in lumbar spinal stenosis. *Am J Phys Med Rehabil*. 2006;85(2):135-140.  
7 doi:10.1097/01.phm.0000197586.91860.a1  
8
- 9 Barboi AC, Barkhaus PE. Electrodiagnostic testing in neuromuscular disorders. *Neurol*  
10 *Clin*. 2004;22(3):619-vi. doi:10.1016/j.ncl.2004.03.007  
11
- 12 Biedermann HJ, Shanks GL, Forrest WJ, Inglis J. Power spectrum analyses of  
13 electromyographic activity. Discriminators in the differential assessment of patients  
14 with chronic low-back pain. *Spine (Phila Pa 1976)*. 1991;16(10):1179-1184  
15
- 16 Bollu, PC. Single-fiber EMG. *eMedicine Specialties. Neurology. Electromyography and*  
17 *Nerve Conduction Studies*. Updated March 2019. Retrieved on July 4, 2024 from  
18 <http://www.emedicine.com/neuro/topic343.htm>  
19
- 20 Bose B, Wierzbowski LR, Sestokas AK. Neurophysiologic monitoring of spinal nerve root  
21 function during instrumented posterior lumbar spine surgery. *Spine (Phila Pa 1976)*.  
22 2002;27(13):1444-1450. doi:10.1097/00007632-200207010-00014  
23
- 24 Braunwald: Harrison's Principles of Internal Medicine. Electrophysiology studies of  
25 muscle and nerve: Electrophysiologic studies of the central and peripheral nervous  
26 systems. ©2001, The McGraw-Hill Companies, Inc. Chapter 357  
27
- 28 Calfee RP, Dale AM, Ryan D, Descatha A, Franzblau A, Evanoff B. Performance of  
29 simplified scoring systems for hand diagrams in carpal tunnel syndrome screening. *J*  
30 *Hand Surg Am*. 2012;37(1):10-17. doi:10.1016/j.jhsa.2011.08.016  
31
- 32 Centers for Medicare and Medicaid Services (CMS). Local Coverage Determination  
33 (LCD): NERVE CONDUCTION Studies and Electromyography (L36526). Retrieved  
34 on July 4, 2024 from [https://www.cms.gov/medicare-coverage-](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36526&ver=32&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=%26mdash%3b)  
35 [database/view/lcd.aspx?lcdid=36526&ver=32&SearchType=Advanced&CoverageSel-](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36526&ver=32&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=%26mdash%3b)  
36 [ection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36526&ver=32&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=%26mdash%3b)  
37 [&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=%26mdash%3b](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36526&ver=32&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=%26mdash%3b)  
38
- 39 Chang MH, Liu LH, Lee YC, Wei SJ, Chiang HL, Hsieh PF. Comparison of sensitivity of  
40 transcarpal median motor conduction velocity and conventional conduction techniques  
41 in electrodiagnosis of carpal tunnel syndrome. *Clin Neurophysiol*. 2006;117(5):984-  
42 991. doi:10.1016/j.clinph.2006.01.015



- 1 Chawla J, Burneo JG, Barkley GL. Clinical Applications of Somatosensory Evoked  
2 Potentials. Medscape. Updated Aug 2019. Retrieved on July 4, 2024 from  
3 <http://emedicine.medscape.com/article/1139393-overview#showall>  
4
- 5 Chiappa K. Electrophysiologic monitoring during carotid endarterectomies. In: Chiappa  
6 K, editor. Evoked potentials in clinical medicine. Third edition. ©1997. Lippincott-  
7 Raven Publishers. Philadelphia –New York. Ch. 19  
8
- 9 Chiappa K, Cros D. Dermatomal somatosensory evoked potentials. In: Chiappa K, editor.  
10 Evoked potentials in clinical medicine. Third edition. ©1997. Lippincott-Raven  
11 Publishers. Philadelphia –New York. Ch. 12  
12
- 13 Cho SC, Ferrante MA, Levin KH, Harmon RL, So YT. Utility of electrodiagnostic testing  
14 in evaluating patients with lumbosacral radiculopathy: An evidence-based  
15 review. Muscle Nerve. 2010;42(2):276-282. doi:10.1002/mus.21759  
16
- 17 Choi JM, Di Maria G. Electrodiagnostic Testing for Disorders of Peripheral Nerves. Clin  
18 Geriatr Med. 2021;37(2):209-221. doi:10.1016/j.cger.2021.01.010  
19
- 20 Collins GA, Cohen MJ, Naliboff BD, Schandler SL. Comparative analysis of paraspinal  
21 and frontalis EMG, heart rate and skin conductance in chronic low back pain patients  
22 and normals to various postures and stress. Scand J Rehabil Med. 1982;14(1):39-46  
23
- 24 Cruccu G, Aminoff MJ, Curio G, et al. Recommendations for the clinical use of  
25 somatosensory-evoked potentials. Clin Neurophysiol. 2008;119(8):1705-1719.  
26 doi:10.1016/j.clinph.2008.03.016  
27
- 28 Crum BA, Strommen JA. Peripheral nerve stimulation and monitoring during operative  
29 procedures. Muscle Nerve. 2007;35(2):159-170. doi:10.1002/mus.20707  
30
- 31 Dale AM, Agboola F, Yun A, Zeringue A, Al-Lozi MT, Evanoff B. Comparison of  
32 automated versus traditional nerve conduction study methods for median nerve testing  
33 in a general worker population. PM R. 2015;7(3):276-282.  
34 doi:10.1016/j.pmrj.2014.10.003  
35
- 36 Danneels LA, Cagnie BJ, Cools AM, et al. Intra-operator and inter-operator reliability of  
37 surface electromyography in the clinical evaluation of back muscles. Man Ther.  
38 2001;6(3):145-153. doi:10.1054/math.2001.0396  
39
- 40 DeGood DE, Stewart WR, Adams LE, Dale JA. Paraspinal EMG and autonomic reactivity  
41 of patients with back pain and controls to personally relevant stress. Percept Mot Skills.  
42 1994;79(3 Pt 1):1399-1409. doi:10.2466/pms.1994.79.3.1399

- 1 Derr JJ, Micklesen PJ, Robinson LR. Predicting recovery after fibular nerve injury: which  
2 electrodiagnostic features are most useful?. *Am J Phys Med Rehabil.* 2009;88(7):547-  
3 553. doi:10.1097/PHM.0b013e3181a9f519  
4
- 5 De Sousa EA, Chin RL, Sander HW, Latov N, Brannagan TH 3rd. Demyelinating findings  
6 in typical and atypical chronic inflammatory demyelinating polyneuropathy: sensitivity  
7 and specificity. *J Clin Neuromuscul Dis.* 2009;10(4):163-169.  
8 doi:10.1097/CND.0b013e31819a71e1  
9
- 10 de Souza RJ, de Souza A, Nagvekar MD. Nerve conduction studies in diabetics  
11 presymptomatic and symptomatic for diabetic polyneuropathy. *J Diabetes*  
12 *Complications.* 2015;29(6):811-817. doi:10.1016/j.jdiacomp.2015.05.009  
13
- 14 Devlin VJ, Schwartz DM. Intraoperative neurophysiologic monitoring during spinal  
15 surgery. *J Am Acad Orthop Surg.* 2007;15(9):549-560. doi:10.5435/00124635-  
16 200709000-00005  
17
- 18 Drost G, Stegeman DF, van Engelen BG, Zwarts MJ. Clinical applications of high-density  
19 surface EMG: a systematic review. *J Electromyogr Kinesiol.* 2006;16(6):586-602.  
20 doi:10.1016/j.jelekin.2006.09.005  
21
- 22 Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms versus nerve conduction studies  
23 to diagnose diabetic sensorimotor polyneuropathy: CI vs. NPhys trial. *Muscle Nerve.*  
24 2010;42(2):157-164. doi:10.1002/mus.21661  
25
- 26 Eager M, Shimer A, Jahangiri FR, Shen F, Arlet V. Intraoperative neurophysiological  
27 monitoring (IONM): lessons learned from 32 case events in 2069 spine cases. *Am J*  
28 *Electroneurodiagnostic Technol.* 2011;51(4):247-263  
29
- 30 Edwards BM, Kileny PR. Intraoperative neurophysiologic monitoring: indications and  
31 techniques for common procedures in otolaryngology-head and neck  
32 surgery. *Otolaryngol Clin North Am.* 2005;38(4):631-viii.  
33 doi:10.1016/j.otc.2005.03.002  
34
- 35 Eisen and Fischer. *The F Wave. Recommendations for the Practice of Clinical*  
36 *Neurophysiology: Guidelines of the International Federation of Clinical Physiology*  
37 *(EEG Suppl. 52)* Editors: G. Deuschl and A. Eisen, 1999  
38
- 39 Elkowitz SJ, Dubin NH, Richards BE, Wilgis EF. Clinical utility of portable versus  
40 traditional electrodiagnostic testing for diagnosing, evaluating, and treating carpal  
41 tunnel syndrome. *Am J Orthop (Belle Mead NJ).* 2005;34(8):362-364.

- 1 Emerson RG, Adams DC, Nagle KJ. Monitoring of spinal cord function intraoperatively  
2 using motor and somatosensory evoked potentials. In: Chiappa K, editor. Evoked  
3 potentials in clinical medicine. Third edition. ©1997. Lippincott-Raven Publishers.  
4 Philadelphia –New York. Ch 20  
5
- 6 Emeryk-Szajewska B, Badurska B, Kostera-Pruszczyk A. Electrophysiological findings in  
7 hereditary motor and sensory neuropathy type I and II--a conduction velocity  
8 study. *Electromyogr Clin Neurophysiol*. 1998;38(2):95-101  
9
- 10 England JD, Franklin GM. Automated hand-held nerve conduction devices: raw data, raw  
11 interpretations. *Muscle Nerve*. 2011;43(1):6-8. doi:10.1002/mus.21960  
12
- 13 Erickson L, Costa V, McGregor M. Intraoperative neurophysiological monitoring during  
14 spinal surgery. Montreal: Technology Assessment Unit of the McGill University  
15 Health Centre (MUHC), 2005:39  
16
- 17 Fehlings MG, Brodke DS, Norvell DC, Dettori JR. The evidence for intraoperative  
18 neurophysiological monitoring in spine surgery: does it make a difference?. *Spine*  
19 (Phila Pa 1976). 2010;35(9 Suppl):S37-S46. doi:10.1097/BRS.0b013e3181d8338e  
20
- 21 Ferdjallah M, Wertsch JJ. Anatomical and technical considerations in surface  
22 electromyography. *Phys Med Rehabil Clin N Am*. 1998;9(4):925-931  
23
- 24 Fisher MA. H reflexes and F waves. Fundamentals, normal and abnormal patterns. *Neurol*  
25 *Clin*. 2002;20(2):339-vi. doi:10.1016/s0733-8619(01)00004-4  
26
- 27 Fisher MA, Bajwa R, Somashekar KN. Routine electrodiagnosis and a multiparameter  
28 technique in lumbosacral radiculopathies. *Acta Neurol Scand*. 2008;118(2):99-105.  
29 doi:10.1111/j.1600-0404.2007.00987.x  
30
- 31 Geisser ME, Ranavaya M, Haig AJ, et al. A meta-analytic review of surface  
32 electromyography among persons with low back pain and normal, healthy controls. *J*  
33 *Pain*. 2005;6(11):711-726. doi:10.1016/j.jpain.2005.06.008  
34
- 35 Gooch CL, Pullman S. Electromyography, nerve conduction studies, and magnetic  
36 stimulation. In: Rowland PL, editor. *Merritt's Neurology*. 11th edition. Lippincott  
37 Williams and Wilkins. Ch 15  
38
- 39 Gooch CL, Weimer LH. The electrodiagnosis of neuropathy: basic principles and common  
40 pitfalls. *Neurol Clin*. 2007;25(1):1-28. doi:10.1016/j.ncl.2007.01.011

- 1 Grassme R, Arnold D, Anders Ch, et al. Improved evaluation of back muscle SEMG  
2 characteristics by modelling. *Pathophysiology*. 2005;12(4):307-312.  
3 doi:10.1016/j.pathophys.2005.09.011  
4
- 5 Gunnarsson T, Krassioukov AV, Sarjeant R, Fehlings MG. Real-time continuous  
6 intraoperative electromyographic and somatosensory evoked potential recordings in  
7 spinal surgery: correlation of clinical and electrophysiologic findings in a prospective,  
8 consecutive series of 213 cases. *Spine (Phila Pa 1976)*. 2004;29(6):677-684.  
9 doi:10.1097/01.brs.0000115144.30607.e9  
10
- 11 Guse BH, Love MJ. Medical assessment and laboratory testing in psychiatry. In: Saydock  
12 BJ, Saydock VA, editors. *Kaplan and Saydock's Comprehensive Textbook of  
13 Psychiatry*. 8th ed, 2005. p. 919.  
14
- 15 Haig AJ, Gelblum JB, Rechten JJ, Gitter AJ. Technology assessment: the use of surface  
16 EMG in the diagnosis and treatment of nerve and muscle disorders. *Muscle Nerve*.  
17 1996;19(3):392-395. doi:10.1002/(SICI)1097-4598(199603)19:3<392::AID-  
18 MUS21>3.0.CO;2-T  
19
- 20 Haig AJ, Tong HC, Yamakawa KS, et al. Spinal stenosis, back pain, or no symptoms at  
21 all? A masked study comparing radiologic and electrodiagnostic diagnoses to the  
22 clinical impression. *Arch Phys Med Rehabil*. 2006;87(7):897-903.  
23 doi:10.1016/j.apmr.2006.03.016  
24
- 25 Hammad M, Silva A, Glass J, Sladky JT, Benatar M. Clinical, electrophysiologic, and  
26 pathologic evidence for sensory abnormalities in ALS. *Neurology*. 2007;69(24):2236-  
27 2242. doi:10.1212/01.wnl.0000286948.99150.16  
28
- 29 Heinonen P, Kautiainen H, Mikkelsen M. Erector spinae SEMG activity during forward  
30 flexion and re-extension in ankylosing spondylitis patients. *Pathophysiology*.  
31 2005;12(4):289-293. doi:10.1016/j.pathophys.2005.09.010  
32
- 33 Hilburn JW. General principles and use of electrodiagnostic studies in carpal and cubital  
34 tunnel syndromes. With special, attention to pitfalls and interpretation. *Hand Clin*.  
35 1996;12(2):205-221.  
36
- 37 Hogrel JY. Clinical applications of surface electromyography in neuromuscular  
38 disorders. *Neurophysiol Clin*. 2005;35(2-3):59-71. doi:10.1016/j.neucli.2005.03.001  
39
- 40 Höliner I, Haslinger V, Lütchg J, et al. Validity of the neurological examination in  
41 diagnosing diabetic peripheral neuropathy. *Pediatr Neurol*. 2013;49(3):171-177.  
42 doi:10.1016/j.pediatrneurol.2013.03.014

- 1 Holland NR. Intraoperative electromyography. *J Clin Neurophysiol.* 2002;19(5):444-453.  
2 doi:10.1097/00004691-200210000-00007  
3
- 4 Hu Y, Kwok JW, Tse JY, Luk KD. Time-varying surface electromyography topography as  
5 a prognostic tool for chronic low back pain rehabilitation. *Spine J.* 2014;14(6):1049-  
6 1056. doi:10.1016/j.spinee.2013.11.060  
7
- 8 Jablecki CK, Andary MT, Floeter MK, et al. Practice parameter: Electrodiagnostic studies  
9 in carpal tunnel syndrome. Report of the American Association of Electrodiagnostic  
10 Medicine, American Academy of Neurology, and the American Academy of Physical  
11 Medicine and Rehabilitation (Retired). *Neurology.* 2002;58(11):1589-1592.  
12 doi:10.1212/wnl.58.11.1589  
13
- 14 Jabre JF, Salzsieder BT, Gnemi KE. Criterion validity of the NC-stat automated nerve  
15 conduction measurement instrument. *Physiol Meas.* 2007;28(1):95-104.  
16 doi:10.1088/0967-3334/28/1/009  
17
- 18 Jalovaara P, Niinimäki T, Vanharanta H. Pocket-size, portable surface EMG device in the  
19 differentiation of low back pain patients. *Eur Spine J.* 1995;4(4):210-212.  
20 doi:10.1007/BF00303412  
21
- 22 Jameson LC, Janik DJ, Sloan TB. Electrophysiologic monitoring in  
23 neurosurgery. *Anesthesiol Clin.* 2007;25(3):605-x. doi:10.1016/j.anclin.2007.05.004  
24
- 25 Juel VC. Evaluation of neuromuscular junction disorders in the electromyography  
26 laboratory. *Neurol Clin.* 2012;30(2):621-639. doi:10.1016/j.ncl.2011.12.012  
27
- 28 Jurell KC. Surface EMG and fatigue. *Phys Med Rehabil Clin N Am.* 1998;9(4):933-ix  
29
- 30 Karami-Mohajeri S, Nikfar S, Abdollahi M. A systematic review on the nerve-muscle  
31 electrophysiology in human organophosphorus pesticide exposure. *Hum Exp Toxicol.*  
32 2014;33(1):92-102. doi:10.1177/0960327113489047  
33
- 34 Katifi HA, Sedgwick EM. Evaluation of the dermatomal somatosensory evoked potential  
35 in the diagnosis of lumbo-sacral root compression. *J Neurol Neurosurg Psychiatry.*  
36 1987;50(9):1204-1210. doi:10.1136/jnnp.50.9.1204  
37
- 38 Katirji B. The clinical electromyography examination. An overview. *Neurol Clin.*  
39 2002;20(2):291-v. doi:10.1016/s0733-8619(01)00002-0  
40
- 41 Katz JN, Simmons BP. Clinical practice. Carpal tunnel syndrome. *N Engl J Med.*  
42 2002;346(23):1807-1812. doi:10.1056/NEJMcp013018

- 1 Katz RT. NC-stat as a screening tool for carpal tunnel syndrome in industrial workers. *J*  
 2 *Occup Environ Med.* 2006;48(4):414-418. doi:10.1097/01.jom.0000194151.30385.1a  
 3
- 4 Kaufman MA. Differential diagnosis and pitfalls in electrodiagnostic studies and special  
 5 tests for diagnosing compressive neuropathies. *Orthop Clin North Am.*  
 6 1996;27(2):245-252  
 7
- 8 Kelleher MO, Tan G, Sarjeant R, Fehlings MG. Predictive value of intraoperative  
 9 neurophysiological monitoring during cervical spine surgery: a prospective analysis of  
 10 1055 consecutive patients. *J Neurosurg Spine.* 2008;8(3):215-221.  
 11 doi:10.3171/SPI/2008/8/3/215  
 12
- 13 Khan MH, Smith PN, Balzer JR, et al. Intraoperative somatosensory evoked potential  
 14 monitoring during cervical spine corpectomy surgery: experience with 508  
 15 cases. *Spine (Phila Pa 1976).* 2006;31(4):E105-E113.  
 16 doi:10.1097/01.brs.0000200163.71909.1f  
 17
- 18 Kong X, Gozani SN, Hayes MT, Weinberg DH. NC-stat sensory nerve conduction studies  
 19 in the median and ulnar nerves of symptomatic patients. *Clin Neurophysiol.*  
 20 2006;117(2):405-413. doi:10.1016/j.clinph.2005.10.019  
 21
- 22 Kong X, Lesser EA, Megerian JT, Gozani SN. Repeatability of nerve conduction  
 23 measurements using automation. *J Clin Monit Comput.* 2006;20(6):405-410.  
 24 doi:10.1007/s10877-006-9046-8  
 25
- 26 Kostera-Pruszczyk A, Rowińska-Marcińska K, Owsiak S, Jezierski P, & Emeryk-  
 27 Szajewska B. Amplituda fali F w uszkodzeniach obwodowego układu nerwowego [F-  
 28 wave amplitude in peripheral nervous system lesions]. *Neurologia i neurochirurgia*  
 29 *polska.* 2004;38(6):465–470  
 30
- 31 Kraft GH. Dermatomal somatosensory-evoked potentials in the evaluation of lumbosacral  
 32 spinal stenosis. *Phys Med Rehabil Clin N Am.* 2003;14(1):71-75. doi:10.1016/s1047-  
 33 9651(02)00080-3  
 34
- 35 Krassioukov AV, Sarjeant R, Arkia H, Fehlings MG. Multimodality intraoperative  
 36 monitoring during complex lumbosacral procedures: indications, techniques, and long-  
 37 term follow-up review of 61 consecutive cases. *J Neurosurg Spine.* 2004;1(3):243-253.  
 38 doi:10.3171/spi.2004.1.3.0243  
 39
- 40 Krivickas LS. Electrodiagnosis in neuromuscular disease. *Phys Med Rehabil Clin N Am.*  
 41 1998;9(1):83-vi

- 1 Kwon BC, Jung KI, Baek GH. Comparison of sonography and electrodiagnostic testing in  
 2 the diagnosis of carpal tunnel syndrome. *J Hand Surg Am.* 2008;33(1):65-71.  
 3 doi:10.1016/j.jhsa.2007.10.014  
 4
- 5 Lall RR, Lall RR, Hauptman JS, et al. Intraoperative neurophysiological monitoring in  
 6 spine surgery: indications, efficacy, and role of the preoperative checklist. *Neurosurg*  
 7 *Focus.* 2012;33(5):E10. doi:10.3171/2012.9.FOCUS12235  
 8
- 9 Lange DJ, Trojaborg W. Electromyography and nerve conduction studies in neuromuscular  
 10 disease. In: Merritt's Neurology. Chapter 15. Copyright 2000 by Lippincott Williams  
 11 & Wilkins  
 12
- 13 Larivière C, Arsenault AB, Gravel D, Gagnon D, Loisel P. Evaluation of measurement  
 14 strategies to increase the reliability of EMG indices to assess back muscle fatigue and  
 15 recovery. *J Electromyogr Kinesiol.* 2002;12(2):91-102. doi:10.1016/s1050-  
 16 6411(02)00011-1  
 17
- 18 Larivière C, Gagnon D, Loisel P. The comparison of trunk muscles EMG activation  
 19 between subjects with and without chronic low back pain during flexion-extension and  
 20 lateral bending tasks. *J Electromyogr Kinesiol.* 2000;10(2):79-91. doi:10.1016/s1050-  
 21 6411(99)00027-9  
 22
- 23 Leffler CT, Gozani SN, Cros D. Median neuropathy at the wrist: diagnostic utility of  
 24 clinical findings and an automated electrodiagnostic device. *J Occup Environ Med.*  
 25 2000;42(4):398-409. doi:10.1097/00043764-200004000-00015  
 26
- 27 Legatt AD. General Principles of Somatosensory Evoked Potentials: MedScape. Updated  
 28 Feb 2019. Retrieved on July 4, 2024 from  
 29 <http://emedicine.medscape.com/article/1139906-overview>  
 30
- 31 Lehman GJ, McGill SM. The importance of normalization in the interpretation of surface  
 32 electromyography: a proof of principle. *J Manipulative Physiol Ther.* 1999;22(7):444-  
 33 446. doi:10.1016/s0161-4754(99)70032-1  
 34
- 35 Lehman RM. A review of neurophysiological testing. *Neurosurg Focus.* 2004;16(4):ECP1.  
 36 Published 2004 Apr 15. doi:10.3171/foc.2004.16.4.14  
 37
- 38 Lesser EA, Starr J, Kong X, Megerian JT, Gozani SN. Point-of-service nerve conduction  
 39 studies: an example of industry-driven disruptive innovation in health care. *Perspect*  
 40 *Biol Med.* 2007;50(1):40-53. doi:10.1353/pbm.2007.0007

- 1 Linden RD, Zappulla R, Shileds CB. Intraoperative evoked potential monitoring. In:  
2 Chiappa K, editor. Evoked potentials in clinical medicine. Third edition. ©1997.  
3 Lippincott-Raven Publishers. Philadelphia – New York. Ch. 18  
4
- 5 Liu X, Aziz TZ, Bain PG. Intraoperative monitoring of motor symptoms using surface  
6 electromyography during stereotactic surgery for movement disorders. *J Clin*  
7 *Neurophysiol.* 2005;22(3):183-191  
8  
9
- 10 Lofland KR, Cassisi JE, Levin JB, Palumbo NL, Blonsky ER. The incremental validity of  
11 lumbar surface EMG, behavioral observation, and a symptom checklist in the  
12 assessment of patients with chronic low-back pain. *Appl Psychophysiol Biofeedback.*  
13 2000;25(2):67-78. doi:10.1023/a:1009589524042  
14
- 15 Maccabee PJ, Eberle LP, Stein IA, et al. Upper leg conduction time distinguishes  
16 demyelinating neuropathies. *Muscle Nerve.* 2011;43(4):518-530.  
17 doi:10.1002/mus.21909  
18
- 19 Mahla ME, Black S, Cucchiara RF. Intraoperative monitoring of sensory evoked potentials.  
20 In: Miller RD, editor. *Miller’s Anesthesia*, 6th ed. Ch 38. Neurologic monitoring.  
21 Copyright © 2005. Churchill Livingstone  
22
- 23 Malhotra NR, Shaffrey CI. Intraoperative electrophysiological monitoring in spine  
24 surgery. *Spine (Phila Pa 1976).* 2010;35(25):2167-2179.  
25 doi:10.1097/BRS.0b013e3181f6f0d0  
26
- 27 Marciniak C, Armon C, Wilson J, Miller R. Practice parameter: utility of electrodiagnostic  
28 techniques in evaluating patients with suspected peroneal neuropathy: an evidence-  
29 based review. *Muscle Nerve.* 2005;31(4):520-527. doi:10.1002/mus.20308  
30
- 31 Meekins GD, So Y, Quan D. American Association of Neuromuscular & Electrodiagnostic  
32 Medicine evidenced-based review: use of surface electromyography in the diagnosis  
33 and study of neuromuscular disorders. *Muscle Nerve.* 2008;38(4):1219-1224.  
34 doi:10.1002/mus.21055  
35
- 36 Megerian JT, Kong X, Gozani SN. Utility of nerve conduction studies for carpal tunnel  
37 syndrome by family medicine, primary care, and internal medicine physicians. *J Am*  
38 *Board Fam Med.* 2007;20(1):60-64. doi:10.3122/jabfm.2007.01.060111  
39
- 40 Mendell JR, Sahenk Z. Clinical practice. Painful sensory neuropathy. *N Engl J Med.*  
41 2003;348(13):1243-1255. doi:10.1056/NEJMcp022282



- 1 Meriggioli MN, Sanders DB. Advances in the diagnosis of neuromuscular junction  
2 disorders. *Am J Phys Med Rehabil.* 2005;84(8):627-638.  
3 doi:10.1097/01.phm.0000171169.79816.4c  
4
- 5 Mesrati F, Vecchierini MF. F-waves: neurophysiology and clinical value. *Neurophysiol*  
6 *Clin.* 2004;34(5):217-243. doi:10.1016/j.neucli.2004.09.005  
7
- 8 Mohseni Bandpei MA, Rahmani N, Majdoleslam B, Abdollahi I, Ali SS, Ahmad A.  
9 Reliability of surface electromyography in the assessment of paraspinal muscle fatigue:  
10 an updated systematic review. *J Manipulative Physiol Ther.* 2014;37(7):510-521.  
11 doi:10.1016/j.jmpt.2014.05.006  
12
- 13 Molloy FM, Shill HA, Kaelin-Lang A, Karp BI. Accuracy of muscle localization without  
14 EMG: implications for treatment of limb dystonia. *Neurology.* 2002;58(5):805-807.  
15 doi:10.1212/wnl.58.5.805  
16
- 17 Mondelli M, Aretini A, Arrigucci U, Ginanneschi F, Greco G, Sicurelli F. Clinical findings  
18 and electrodiagnostic testing in 108 consecutive cases of lumbosacral radiculopathy  
19 due to herniated disc. *Neurophysiol Clin.* 2013;43(4):205-215.  
20 doi:10.1016/j.neucli.2013.05.004  
21
- 22 Mullins GM, O'Sullivan SS, Neligan A, et al. Non-traumatic brachial plexopathies,  
23 clinical, radiological and neurophysiological findings from a tertiary centre. *Clin*  
24 *Neurol Neurosurg.* 2007;109(8):661-666. doi:10.1016/j.clineuro.2007.05.010  
25
- 26 NeuMed®, Inc. Brevio® Nerve Conduction Monitoring System. Retrieved on July 4,  
27 2024 from <http://www.neumedinc.com/products/brevio.htm>  
28
- 29 NeuroMetrix®. Product Information NC-Stat®/ DPN Check®. Retrieved on July 4, 2024  
30 from <http://www.dpncheck.com/>  
31
- 32 Ney JP, van der Goes DN. Evidence-based guideline update: Intraoperative spinal  
33 monitoring with somatosensory and transcranial electrical motor evoked potentials.  
34 Report of the Therapeutics and Technology Assessment Subcommittee of the  
35 American Academy of Neurology and the American Clinical Neurophysiology  
36 Society. *Neurology.* 2012;79(3):292-294. doi:10.1212/WNL.0b013e3182637c24  
37
- 38 Ng JK, Kippers V, Parnianpour M, Richardson CA. EMG activity normalization for trunk  
39 muscles in subjects with and without back pain. *Med Sci Sports Exerc.*  
40 2002;34(7):1082-1086. doi:10.1097/00005768-200207000-00005

- 1 Ng JK, Richardson CA, Parnianpour M, Kippers V. EMG activity of trunk muscles and  
2 torque output during isometric axial rotation exertion: a comparison between back pain  
3 patients and matched controls. *J Orthop Res.* 2002;20(1):112-121. doi:10.1016/S0736-  
4 0266(01)00067-5
- 5
- 6 Ng JK, Richardson CA, Parnianpour M, Kippers V. Fatigue-related changes in torque  
7 output and electromyographic parameters of trunk muscles during isometric axial  
8 rotation exertion: an investigation in patients with back pain and in healthy  
9 subjects. *Spine (Phila Pa 1976).* 2002;27(6):637-646. doi:10.1097/00007632-  
10 200203150-00013
- 11
- 12 North American Spine Society. Electromyogram and nerve conduction study. North  
13 American Spine Society. Retrieved on July 4, 2024 from  
14 [https://www.spine.org/KnowYourBack/Treatments/AssessmentTools/Electrodiagnost  
15 icTesting](https://www.spine.org/KnowYourBack/Treatments/AssessmentTools/ElectrodiagnosticTesting)
- 16
- 17 Nuwer MR, Emerson RG, Galloway G, et al. Evidence-based guideline update:  
18 intraoperative spinal monitoring with somatosensory and transcranial electrical motor  
19 evoked potentials: report of the Therapeutics and Technology Assessment  
20 Subcommittee of the American Academy of Neurology and the American Clinical  
21 Neurophysiology Society. *Neurology.* 2012;78(8):585-589.  
22 doi:10.1212/WNL.0b013e318247fa0e
- 23
- 24 Oddsson LI, Giphart JE, Buijs RJ, Roy SH, Taylor HP, De Luca CJ. Development of new  
25 protocols and analysis procedures for the assessment of LBP by surface EMG  
26 techniques. *J Rehabil Res Dev.* 1997;34(4):415-426
- 27
- 28 Oh SJ. *Clinical Electromyography: Nerve Conduction Studies.* 3d ed. Philadelphia, PA:  
29 Lippincott Williams & Wilkins; 2003: 147-148
- 30
- 31 Omejec G, Žgur T, Podnar S. Diagnostic accuracy of ultrasonographic and nerve  
32 conduction studies in ulnar neuropathy at the elbow. *Clin Neurophysiol.*  
33 2015;126(9):1797-1804. doi:10.1016/j.clinph.2014.12.001
- 34
- 35 Palmieri RM, Ingersoll CD, Hoffman MA. The hoffmann reflex: methodologic  
36 considerations and applications for use in sports medicine and athletic training  
37 research. *J Athl Train.* 2004;39(3):268-277
- 38
- 39 Park KM, Shin KJ, Park J, Ha SY, Kim SE. The usefulness of terminal latency index of  
40 median nerve and f-wave difference between median and ulnar nerves in assessing the  
41 severity of carpal tunnel syndrome. *J Clin Neurophysiol.* 2014;31(2):162-168.  
42 doi:10.1097/WNP.0000000000000041

- 1 Parker SL, Amin AG, Farber SH, et al. Ability of electromyographic monitoring to  
2 determine the presence of malpositioned pedicle screws in the lumbosacral spine:  
3 analysis of 2450 consecutively placed screws. *J Neurosurg Spine*. 2011;15(2):130-135.  
4 doi:10.3171/2011.3.SPINE101
- 5
- 6 Pawar S, Kashikar A, Shende V, Waghmare S. The study of diagnostic efficacy of nerve  
7 conduction study parameters in cervical radiculopathy. *J Clin Diagn Res*.  
8 2013;7(12):2680-2682. doi:10.7860/JCDR/2013/7545.3731
- 9
- 10 Peach JP, McGill SM. Classification of low back pain with the use of spectral  
11 electromyogram parameters. *Spine (Phila Pa 1976)*. 1998;23(10):1117-1123.  
12 doi:10.1097/00007632-199805150-00009
- 13
- 14 Pelosi L, Lamb J, Grevitt M, Mehdian SM, Webb JK, Blumhardt LD. Combined  
15 monitoring of motor and somatosensory evoked potentials in orthopaedic spinal  
16 surgery. *Clin Neurophysiol*. 2002;113(7):1082-1091. doi:10.1016/s1388-  
17 2457(02)00027-5
- 18
- 19 Perkins BA, Grewal J, Ng E, Ngo M, Bril V. Validation of a novel point-of-care nerve  
20 conduction device for the detection of diabetic sensorimotor polyneuropathy. *Diabetes*  
21 *Care*. 2006;29(9):2023-2027. doi:10.2337/dc08-0500
- 22
- 23 Perkins BA, Orszag A, Grewal J, Ng E, Ngo M, Bril V. Multi-site testing with a point-of-  
24 care nerve conduction device can be used in an algorithm to diagnose diabetic  
25 sensorimotor polyneuropathy. *Diabetes Care*. 2008;31(3):522-524. doi:10.2337/dc07-  
26 1227
- 27
- 28 Pullman SL, Goodin DS, Marquez AI, Tabbal S, Rubin M. Clinical utility of surface  
29 EMG: report of the therapeutics and technology assessment subcommittee of the  
30 American Academy of Neurology (Retired). *Neurology*. 2000;55(2):171-177.  
31 doi:10.1212/wnl.55.2.171
- 32
- 33 Rau, G., Disselhorst-Klug, C., & Silny, J. (1997). Noninvasive approach to motor unit  
34 characterization: Muscle structure, membrane dynamics and neuronal control. *Journal*  
35 *of Biomechanics*, 30(5), 441-446
- 36
- 37 Raynor BL, Lenke LG, Bridwell KH, Taylor BA, Padberg AM. Correlation between low  
38 triggered electromyographic thresholds and lumbar pedicle screw malposition: analysis  
39 of 4857 screws. *Spine (Phila Pa 1976)*. 2007;32(24):2673-2678.  
40 doi:10.1097/BRS.0b013e31815a524f

- 1 Resnick DK, Choudhri TF, Dailey AT, et al. Guidelines for the performance of fusion  
2 procedures for degenerative disease of the lumbar spine. Part 15: electrophysiological  
3 monitoring and lumbar fusion. *J Neurosurg Spine*. 2005;2(6):725-732.  
4 doi:10.3171/spi.2005.2.6.0725  
5
- 6 Rotman MB, Enkvetchakul BV, Megerian JT, Gozani SN. Time course and predictors of  
7 median nerve conduction after carpal tunnel release. *J Hand Surg Am*. 2004;29(3):367-  
8 372. doi:10.1016/j.jhssa.2004.01.011  
9
- 10 Ruddy: Kelley's Textbook of Rheumatology, 6th edition. Neurophysiology  
11 (electrodiagnostic studies). ©2001 W.B. Saunders Company. Page 470.  
12
- 13 Sanders DB, Howard JF. Disorders of neuromuscular transmission. In: Bradley: Neurology  
14 in Clinical Practice, 5th edition. Ch 82. Copyright © 2008 Butterworth-Heinemann.  
15
- 16 Schmidt K, China NM, Sorenson EJ, Strommen JA, Boon AJ. Accuracy of diagnoses  
17 delivered by an automated hand-held nerve conduction device in comparison to  
18 standard electrophysiological testing in patients with unilateral leg symptoms. *Muscle  
19 Nerve*. 2011;43(1):9-13. doi:10.1002/mus.21911  
20
- 21 Schoeck AP, Mellion ML, Gilchrist JM, Christian FV. Safety of nerve conduction studies  
22 in patients with implanted cardiac devices. *Muscle Nerve*. 2007;35(4):521-524.  
23 doi:10.1002/mus.20690  
24
- 25 Seubert CN, Mahla ME. Neurologic monitoring. Ch 46. In: Miller's Anesthesia. 7th ed.  
26 Copyright © 2009 Churchill Livingstone  
27
- 28 Sharan A, Groff MW, Dailey AT, et al. Guideline update for the performance of fusion  
29 procedures for degenerative disease of the lumbar spine. Part 15: electrophysiological  
30 monitoring and lumbar fusion. *J Neurosurg Spine*. 2014;21(1):102-105.  
31 doi:10.3171/2014.4.SPINE14324  
32
- 33 Snowden ML, Haselkorn JK, Kraft GH, et al. Dermatomal somatosensory evoked  
34 potentials in the diagnosis of lumbosacral spinal stenosis: comparison with imaging  
35 studies. *Muscle Nerve*. 1992;15(9):1036-1044. doi:10.1002/mus.880150908  
36
- 37 Souza, T. Differential Diagnosis and Management for the Chiropractor : Protocols and  
38 Algorithms. Fifth. Jones & Bartlett Learning; 2016  
39
- 40 Stålberg E, Falck B. The role of electromyography in neurology. *Electroencephalogr Clin  
41 Neurophysiol*. 1997;103(6):579-598. doi:10.1016/s0013-4694(97)00138-7

- 1 Stegeman DF, Blok JH, Hermens HJ, Roeleveld K. Surface EMG models: properties and  
 2 applications. *J Electromyogr Kinesiol.* 2000;10(5):313-326. doi:10.1016/s1050-  
 3 6411(00)00023-7
- 4
- 5 Storm SA, Kraft GH. The clinical use of dermatomal somatosensory evoked potentials in  
 6 lumbosacral spinal stenosis. *Phys Med Rehabil Clin N Am.* 2004;15(1):107-115.  
 7 doi:10.1016/s1047-9651(03)00107-4
- 8
- 9 Sutter MA, Eggspuehler A, Grob D, Porchet F, Jeszenszky D, Dvorak J. Multimodal  
 10 intraoperative monitoring (MIOM) during 409 lumbosacral surgical procedures in 409  
 11 patients. *Eur Spine J.* 2007;16 Suppl 2(Suppl 2):S221-S228. doi:10.1007/s00586-007-  
 12 0432-9
- 13
- 14 Tankisi H, Pugdahl K, Fuglsang-Frederiksen A, et al. Pathophysiology inferred from  
 15 electrodiagnostic nerve tests and classification of polyneuropathies. Suggested  
 16 guidelines. *Clin Neurophysiol.* 2005;116(7):1571-1580.  
 17 doi:10.1016/j.clinph.2005.04.003
- 18
- 19 Torvin Møller A, Winther Bach F, Feldt-Rasmussen U, et al. Functional and structural  
 20 nerve fiber findings in heterozygote patients with Fabry disease. *Pain.* 2009;145(1-  
 21 2):237-245. doi:10.1016/j.pain.2009.06.032
- 22
- 23 Triano JJ, Budgell B, Bagnulo A, et al. Review of methods used by chiropractors to  
 24 determine the site for applying manipulation. *Chiropr Man Therap.* 2013;21(1):36.  
 25 Published 2013 Oct 21. doi:10.1186/2045-709X-21-36
- 26
- 27 Trujillo-Hernández B, Huerta M, Trujillo X, Vásquez C, Pérez-Vargas D, Millán-Guerrero  
 28 RO. F-wave and H-reflex alterations in recently diagnosed diabetic patients. *J Clin*  
 29 *Neurosci.* 2005;12(7):763-766. doi:10.1016/j.jocn.2004.09.018
- 30
- 31 Tsai TM, Tsai CL, Lin TS, Lin CC, Jou IM. Value of dermatomal somatosensory evoked  
 32 potentials in detecting acute nerve root injury: an experimental study with special  
 33 emphasis on stimulus intensity. *Spine (Phila Pa 1976).* 2005;30(18):E540-E546.  
 34 doi:10.1097/01.brs.0000179311.87137.0d
- 35
- 36 Urban MK. Anesthesia for Orthopedic Surgery. In: Miller: Miller's Anesthesia, 7th edition.  
 37 Ch 70. Copyright © 2009 Churchill Livingstone
- 38
- 39 U.S. Food and Drug Administration (FDA). CFR Title 21. Part 882. Neurological Devices.  
 40 Updated June 2023. Retrieved on July 4, 2024 from  
 41 [http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=882)  
 42 882

- 1 U.S. Food and Drug Administration. Brevio. 510(k) Summary K012069. June 29, 2001.  
2 Retrieved on July 4, 2024 from  
3 [http://www.accessdata.fda.gov/cdrh\\_docs/pdf/k012069.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf/k012069.pdf)  
4
- 5 Vij N, Kiernan H, Miller-Gutierrez S, et al. Etiology Diagnosis and Management of Radial  
6 Nerve Entrapment. *Anesth Pain Med.* 2021;11(1):e112823. Published 2021 Feb 14.  
7 doi:10.5812/aapm.112823  
8
- 9 Wang Y, Cui LY, Chen L, et al. Nerve conduction studies in patients with dermatomyositis  
10 or polymyositis. *Chin Med J (Engl).* 2010;123(5):523-526  
11
- 12 Watson PJ, Booker CK, Main CJ, Chen AC. Surface electromyography in the identification  
13 of chronic low back pain patients: the development of the flexion relaxation ratio. *Clin*  
14 *Biomech (Bristol, Avon).* 1997;12(3):165-171. doi:10.1016/s0268-0033(97)00065-x  
15
- 16 Yiannikas C. Short-latency somatosensory evoked potentials in peripheral nerve lesions,  
17 plexopathies, and radiculopathies. In: Chiappa K, editor. *Evoked potentials in clinical*  
18 *medicine.* Third edition. Lippincott-Raven Publishers ©1997. Philadelphia –New  
19 York. Ch. 10  
20
- 21 Zwarts MJ, Drost G, Stegeman DF. Recent progress in the diagnostic use of surface EMG  
22 for neurological diseases. *J Electromyogr Kinesiol.* 2000;10(5):287-291.  
23 doi:10.1016/s1050-6411(00)00020-1  
24
- 25 Zwarts MJ, Stegeman DF. Multichannel surface EMG: basic aspects and clinical  
26 utility. *Muscle Nerve.* 2003;28(1):1-17. doi:10.1002/mus.10358